At Mylan, we are committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what’s right, not what’s easy; and impact the future through passionate global leadership.
About this Report

Mylan’s Global Social Responsibility 2018 Progress Report offers a company-wide overview of Mylan’s global efforts related to environmental, social and governance (ESG) matters.

The content of the report is based, in part, on an issues assessment conducted in 2018 with internal and external stakeholders and is prepared in accordance with Global Reporting Initiative (GRI) Standards: Core level.¹

Mylan is a signatory to the United Nations Global Compact and is committed to its 10 principles aimed at protecting human rights and the environment and ensuring fair labor and corruption-free business practices. As a Compact signatory, this report constitutes Mylan’s Communication on Progress Report.

Mylan N.V. and certain subsidiaries² are subject to statutory sustainability reporting in the EU, following the EU Non-Financial Reporting Directive (EU NFR). This report, together with Mylan’s statutory filings is intended to fulfill our applicable reporting requirements.

Information contained in this report reflects progress from Jan.1, 2018 – Dec. 31, 2018, unless otherwise noted. Mylan most recently issued its 2017 Progress Report on Global Social Responsibility in May 2018 and intends to continue publishing reports on an annual basis.

More information on Mylan’s work, policies and management processes is available at Mylan.com.

Reporting on other matters specific to financial performance of Mylan N.V. and our subsidiaries can be found in Mylan’s 2018 Annual Report on Form 10-K.

¹Please see the GRI Disclosures index in the Appendix.
²Mylan N.V. in the Netherlands and Meda AB (publ) in Sweden
Publication date: April 2, 2019

ABOUT MYLAN

We offer a robust portfolio of more than 7,500 products, including prescription generic, branded generic, brand-name and biosimilar drugs, as well as over-the-counter (OTC) remedies. We market our products in more than 165 countries and territories, and every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world.

Should you have questions, please contact us at GSR@Mylan.com.

Visit Mylan.com for more information.
2018 HIGHLIGHTS

~35,000 GLOBAL WORKFORCE

81% OF MYLAN EMPLOYEES see a clear link between their work and the company’s mission

>7,500 PRODUCTS GLOBALLY

~59B DOSES SOLD at an average selling price of 19¢ PER DOSE

~40% OF THE NEARLY 22M\(^1\) HIV+ PATIENTS AND 

~60% OF THE WORLD’S HIV+ CHILDREN ON TREATMENT DEPEND ON ONE OF OUR PRODUCTS

>165 COUNTRIES & TERRITORIES REACHED

INCLUDING 90% OF LOW- AND LOWER-MIDDLE INCOME COUNTRIES\(^2\)

REGULATORY APPROVALS FOR BIOSIMILARS IN >65 COUNTRIES

---

\(^1\)http://www.unaids.org
\(^2\)Income groups from the World Bank list of economies (Published June 2018)
2018 HIGHLIGHTS

12 R&D CENTERS
with ~3,700 products\(^1\) pending approval or in development

COLLABORATED WITH >50 ORGANIZATIONS WORLDWIDE ON ISSUES OF GLOBAL PUBLIC HEALTH

BALANCED AND DIVERSE REACH

Net Sales by Segment
- North America 36%
- Europe 37%
- Rest of World 27%

Net Sales by Product Type
- Rx/Bx
- OTC
- Gx

~30\% increase in RENEWABLE ENERGY PURCHASED

68 PRODUCTS\(^2\) on the WHO list of prequalified products

\(^1\) Products taken from internal data and rounded
\(^2\) https://extranet.who.int/prequal/content/prequalified-lists/medicines, as of 2.1.19
Advancing Our Mission

Everyone deserves the opportunity to live a healthy life. All too often, however, circumstances largely beyond an individual’s control, such as geography, ethnicity, economic status and gender, affect the ability to achieve positive health outcomes.

That’s why Mylan’s long tradition of breaking through barriers and pushing boundaries to identify solutions for unmet needs is as important as ever. Our strategy, which is centered around our mission to improve access to medicine, dictates that we continuously work to strengthen and adapt our business model to benefit the patients and communities we serve today as well as those we envision helping in the future. We believe the greatest potential for serving all stakeholders comes from focusing on not just the short-term aspects but also the long-term impact of models that are built around sustainability for all concerned.

In 2018, we continued our efforts by bringing new or improved products and solutions to patient populations around the globe. We also remained engaged with policy leaders in every region on matters related to increasing patient access and choice.

Providing access to medicine means a lot of different things to a lot of different people, especially when it comes to reaching low- and middle-income countries. Our definition of access is making sure the medicine we make is actually getting into the hands of patients in the more than 165 countries and territories we serve. We believe it’s important for this perspective to have a seat at the table whenever reach and impact are being discussed and measured.

As always, there is much work to be done. Healthcare systems throughout the world can and must continue to improve. The U.S., for instance, is undergoing fundamental changes that will impact not only its own healthcare system’s delivery and payment mechanisms, but quite possibly those in other countries as well.

As we work to do our part and contribute to the global dialogue on public health, we remain committed to the United Nations Global Compact and its 10 principles and support the Sustainable Development Goals (SDGs). I was privileged to participate in the U.N. Global Compact CEO Roundtable for the first time in 2018, where an international coalition of leaders discussed equality and human rights and their relationship to business. It remains clear that working with others to identify concrete ways to enhance our contributions to society will maximize our collective impact, ultimately bringing greater health outcomes to people around the world.

This also was a year of continued development for our Global Social Responsibility (GSR) practice. Building upon last year’s momentum, we enhanced our oversight of GSR issues, as well as undertook our most comprehensive analysis to date to identify key social responsibility priorities and better understand our potential to increase our positive impact and reduce risks in the areas that most affect our business and society. The information we gathered informs our strategic planning, and we look forward to gaining even more insights from internal and external stakeholders as we continue our efforts.

As a global healthcare leader, we take seriously our role and the impact we have on the lives of billions across the world. We know that the support of our stakeholders, collaboration with our partners and the dedication of our employees are essential requirements for success. I am grateful for their genuine commitment to work together to face challenges, solve complex issues and – above all – tirelessly seek opportunities to create better health for a better world.

Heather Bresch, CEO
The Sustainable Development Goals (SDGs), adopted by all United Nations Member States in 2015, form the basis for collectively creating a better future by addressing fundamental global challenges such as poverty, poor health, inequality and climate change, among others. Mylan supports the U.N.’s agenda and believes that companies can play a central role in helping to achieve these development goals.

The SDG that is most relevant to our mission and impact is No. 3: Good Health and Well-Being. Our broad and diverse portfolio across 10 therapeutic categories – combined with our long-standing commitment to increasing access to high quality medicine through innovation and partnerships – strongly positions Mylan to make continued contributions toward this goal.

As a global healthcare company, we know our influence and actions impact other goals as well. From ensuring a fair, diverse and safe workplace and upholding a culture of integrity and ethical business practices to supporting local communities and reducing our environmental impact, we are committed to helping lead positive, sustained change.

See page 81 for a full list of the SDGs most relevant to Mylan.
Building Upon Our Heritage
A message from Mylan’s Head of Global Sustainability

At Mylan, we appreciate that the decisions we make and the actions we take can have a lasting impact on the world around us. It’s why we take such pride in the work that we do and why our mission of access is so ingrained throughout our organization. It is also why our commitment to global social responsibility (GSR) is a fundamental component of our aspiration to deliver better health for a better world.

While our GSR governance and reporting efforts have increased in visibility and focus, operating as a responsible member of the communities in which we live, work and serve patients has been a priority for us since our founding. This heritage has helped us achieve meaningful progress in the continuing development of our formal GSR practice over the past year.

Throughout 2018, we increased our engagement with our external stakeholders through meetings with investors, additional communication with our business partners and active participation in GSR-related discussions with non-governmental organizations (NGOs) and industry associations. This interaction provided valuable insights and will continue to inform Mylan’s approach and transparency. As part of our work to put our learnings into action, we:

- Reviewed our policies and activities to identify opportunities to improve our performance and communication related to GSR. As a result, we have further expanded our disclosures throughout the year to better serve our stakeholders. We will maintain these types of regular reviews as our overall approach and capabilities continue to evolve. This is especially relevant given the significant acquisition activity and resulting integration that has occurred within Mylan during the last several years.

- Enhanced our GSR oversight structure by establishing our global sustainability function as a direct report to our CEO. GSR also became an established focus area of Mylan’s Executive Governance Team as well as an emphasis for Mylan’s global Risk Management Team, which was created in 2018. The Risk Oversight Committee of Mylan’s Board of Directors also included oversight of management’s efforts with respect to GSR as a formal component of its Charter in 2018.

- Undertook our first formal process to identify the topics of greatest GSR significance and potential materiality to our business and to our stakeholders. To us, it’s no surprise that the priority topics identified aligned closely with our mission of access. How we implement our overall GSR strategy and the level of success we achieve is dependent upon our ability to understand these topics and plan accordingly.

As we move through 2019, we will continue examining the intersection of our priorities, opportunities and challenges with those of our stakeholders and develop specific social responsibility goals that we plan to share in our next report.

I cannot thank the members of the Mylan team throughout the world enough for their dedication and commitment to global social responsibility. As I have come to know well over the past year, the content of this progress report represents only a sample of the work they are doing both individually and collectively to ensure Mylan makes an impact. I am energized by the opportunity to carry on our work together in 2019 and beyond.

Lara Ramsburg

Our Vision for Global Social Responsibility

Global social responsibility is intrinsically woven within Mylan’s commitment to achieve our mission and deliver better health for a better world. It is what drives our enduring passion to improve access and serve unmet needs across all geographies, while respecting the environment and positively impacting our stakeholders.
OUR GSR ASSESSMENT AND PRIORITIES

Mylan’s 2018 GSR priority assessment was conducted in coordination with a recognized ESG consultant and included:

- GSR-related input from external stakeholder engagements and a comprehensive analysis of reports, publications (including ESG analyses of Mylan) and other written materials representing the GSR viewpoints, concerns and priorities of a broad range of stakeholders, including customers, partners, investors, NGOs, employees, community groups and policy makers; and,
- an internal GSR survey of 60 senior leaders at Mylan, representing key business units and cross-functional areas of our company, spanning Mylan’s geographic footprint.

The issues list below reflects the full universe of GSR topics that were considered in this initial prioritization exercise and the matrix indicates the relative degree of stakeholder interest and potential company impact perceived for the top 15 ranked topics. Five issues – pricing, manufacturing and distribution (including product quality and safety), research and development, access to medicines management and talent management – were identified as GSR priorities based on their overall stakeholder interest and potential impact on Mylan’s business and mission. However, all topics are relevant and important to Mylan, and we recognize our ongoing responsibility to continue to manage each of them diligently and effectively. These topics, and the broader findings of our GSR analysis, form the basis for and are addressed throughout this report and are also being used to inform Mylan’s strategic planning and enterprise risk management efforts.

Complete list of issues assessed:

<table>
<thead>
<tr>
<th>Access to Medicine</th>
<th>Environmental Stewardship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Access to Medicines Management*</td>
<td>Air</td>
</tr>
<tr>
<td>Compliance</td>
<td>Climate Change and Energy</td>
</tr>
<tr>
<td>Local Capacity Building</td>
<td>Environmental Protection</td>
</tr>
<tr>
<td>Manufacturing and Distribution (including product quality &amp; safety)*</td>
<td>Pharmaceuticals in the Environment</td>
</tr>
<tr>
<td>Market Influence</td>
<td>Product Stewardship</td>
</tr>
<tr>
<td>Patents and Licensing</td>
<td>Waste</td>
</tr>
<tr>
<td>Pricing*</td>
<td>Water</td>
</tr>
<tr>
<td>Product Donations</td>
<td>Workplace Health and Safety</td>
</tr>
<tr>
<td>Research and Development*</td>
<td>Operating a Responsible Business</td>
</tr>
</tbody>
</table>

*denotes top 5 priority based upon assessment results

STAKEHOLDER INTEREST

IMPACT ON COMPANY

Patient Outcomes ● Access to Medicines Management ● Business Ethics ● Research & Development ● Pricing ●
Supply Chain ● Manufacturing & Distribution ●
Contribution to Global Public Health ● Employee Engagement ●
Patient Outcomes ● Access to Medicines Management ● Business Ethics ● Research & Development ● Pricing ●
Corporate Governance

Patents and Licensing ● Research and Development ●

At Mylan, we create shared value through our BUSINESS MODEL, integrate social responsibility ACROSS OUR VALUE CHAIN and convey OUR IMPACT: BETTER HEALTH FOR A BETTER WORLD.
OUR COMMITMENT TO ACCESS

Throughout our history, Mylan’s foundation and core business model have been focused on providing access to medicine. Given the significance of patient needs across the globe and across all income levels, we are convinced that meeting this challenge requires a consistent and sustainable commitment. To reinforce that commitment, we have developed access objectives and key performance indicators (KPIs) that flow from our mission statement and seek to describe how we have and will continue to operate universally to fulfill our aim of providing high quality medicines to billions of patients around the world.
OUR MISSION
At Mylan, we are committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we:

• Innovate to satisfy unmet needs
• Make reliability and service excellence a habit
• Do what’s right, not what’s easy
• Impact the future through passionate global leadership

OUR ACCESS OBJECTIVES:
Continuously leverage the breadth, depth and capability of our business model to consistently provide high quality medicine and related services to meet the needs of patients in low-, middle- and high-income countries

Research and develop new dosage forms that will improve effective adherence; alternative product options that will provide more affordable access; and opportunities to bring our existing portfolio to additional countries and regions

Cultivate quality-focused internal and external manufacturing capabilities and services along with pricing approaches that allow for both affordable patient access and sustainable supply

Apply the same commercial and operational focus as well as commitment to quality and safety while supplying products to patients and countries with varying degrees of income level and resources

Seek out opportunities to provide access-related industry and global public health leadership

OUR ACCESS KPIs:
• Doses sold
• Number of products
• Number of countries and territories reached
• Therapeutic categories
• Coverage percentage of the top ten causes of death globally
• Coverage percentage of the top ten causes of death across low- and lower-middle income countries

• Products in development by region
• Products pending approval by region

• Types of products
• Average selling price of Mylan’s medicines
• Customer service levels globally and by region

• Percentage of low- and lower-middle income countries reached
• Doses sold in low- and lower-middle income countries
• Number of products on the World Health Organization’s (WHO) Essential Medicines List
• Number of products on the WHO list of prequalified products (including cross-listed approvals)

• Active partnerships or organizational memberships related to increasing access to medicines
OUR PATH TO PATIENTS

At Mylan, we recognize that effectively meeting the diverse needs of patients in a complex global pharmaceutical marketplace requires dedicated action.

Our approach is designed for long-term, sustainable impact. We’ve built and scaled our commercial, operational and enterprise capabilities to meet the evolving needs of patients and customers in ways that aim to be globally consistent yet locally sensitive. We are grounded by our unwavering commitment to quality; maintaining a broad spectrum of geographic reach, product types and access channels; and offering new product and affordability options. Through our robust research and development (R&D), manufacturing, supply chain and market outreach competencies, we continually are focused on meeting the needs of patients today while also anticipating their needs in the years to come.

Research & Development

In the pharmaceutical industry, R&D is often assumed to reference the development of new, brand-name drugs. However, there are many other components of R&D that are just as critical to providing the world’s population with access to needed medicines. At Mylan, we constantly look for ways to improve patient convenience, prescription compliance, safety, experience and access.

From the development of complex products like biosimilars used to fight cancer and other life-threatening diseases to the creation of heat-stable medications for patients without access to refrigeration and product formulations that can be consumed more easily by children, we’ve invested billions of dollars to more effectively reach patients with a wide variety of health conditions across 10 therapeutic categories and multiple dosage forms.

With 12 R&D centers around the world, including 10 technology-focused development sites and two global R&D centers, Mylan’s scientists develop and implement solutions to address some of the world’s most pressing health concerns. We develop products for patients in low-, middle- and high-income countries with a range of types and expertise that often sets us apart. This process starts with product selection based upon unmet patient needs and continues all the way through to development and regulatory approval. To achieve product approval we must continuously work with various regulatory agencies throughout the globe.

Raw Materials

The active pharmaceutical ingredients (APIs) and other materials and supplies we use in our manufacturing operations are purchased from third parties or produced internally.

Our ability to make or obtain quality raw materials at reasonable prices is crucial to our capability to maximize our impact and supply patients with the finished product medicines they need to maintain their health.
Our more than 40 manufacturing sites, combined with our global supply chain network and the facilities of the many partners with whom we collaborate on manufacturing, development, supply and logistics offer a worldwide, strategically located network of robust size and scope. Designed to reach more patients with more solutions when and where they need them, our regional supply sites are often in close proximity to our key markets and utilize real-time demand and supply data to leverage capabilities and create efficiency and flexibility across our operations.

Wherever we operate, the quality and safety of our products remain our top priorities; our suppliers, contract manufacturers, clinical trial partners and others are expected to comply with the same high standards and regulations as Mylan’s own operations. Consequently, the patients we serve can be confident that the Mylan products they receive are produced with quality in mind.

In 2018:

- We supplied more than 7,500 products with the ability to treat 9 out of the top 10 global causes of death\(^1\,^2\) and reached more than 165 countries and territories, including 90% of low- and lower-middle-income countries,\(^3\) at an average selling price of 19¢ per dose.

---

\(^1\)The remaining cause of death is road injury.


\(^3\)Income groups from the World Bank list of economies (Published June 2018)
Our Impact

01 Patient Health ..................16
02 Employee Health ...............32
03 Environmental Health .........38
04 Global Public Health ..........44
05 Community Health .............52
06 Oversight and Compliance .....58
07 Appendix ..........................68
08 GRI Table ..........................82

Visit Mylan.com for more information.
01
Better Patient Health

CHAPTER SNAPSHOT

Key 2018 Accomplishments
• Launched biosimilars in key markets, progressed several scientific programs and overcame regulatory hurdles
• Procured additional ARV manufacturing capacity in South Africa

Current Challenges
• Addressing supply constraints when they arise
• Adapting to a continually evolving regulatory landscape

Future Opportunities
• Continuing our core generic drug development while also creating more complex and differentiated products for patients
• Creating additional access to more affordable biosimilars
Striving to Meet Patient Needs

We are committed to offering solutions that improve access and advance care for patients at every step of their healthcare journey, from prevention and diagnosis to treatment and supportive care, regardless of where they may live. We do this through our diverse product portfolio, differentiated global manufacturing network and worldwide reach. Our products are capable of addressing 9 of the top 10 causes of death globally and almost 80% of the top causes of death across low- and lower-middle-income countries.¹

To maximize our ability to meet patients’ needs across a variety of health conditions, we focused in 2018 on 10 therapeutic categories. We serve an industry leadership role in many of these areas, with each category containing not just one or two products, but often hundreds of products in a broad range of dosage forms, formulations and delivery systems that allow physicians and patients to tailor care for optimal treatment.

We also offer an evolving number of healthcare solutions to complement our product offerings, such as mobile apps and diagnostics designed to help patients better manage their health. By working with partners, healthcare providers, customers and other stakeholders we strive to make a positive impact by providing people across all incomes with accessible and affordable options to help them live healthier lives.

MYLAN’S THERAPEUTIC CATEGORIES*


*Products taken from internal data as of YE 2018 and rounded
Combating Non-Communicable Diseases

A non-communicable disease (NCD) is a condition that is not transmissible directly from one person to another and can be chronic in nature or acute (a limited duration). According to the U.N., NCDs are the leading cause of death and disability globally. At Mylan, we are continually striving to bring more access to products to ease the burden and impact of NCDs in countries around the world. Some examples of our work in 2018 include:

**Bringing New Options and Convenience to Respiratory and Allergy Patients**

Our ability to help respiratory patients was further expanded in 2018 when the U.S. FDA approved Mylan’s brand drug YUPELRI® for adults with chronic obstructive pulmonary disease (COPD) – the third leading cause of death in the U.S. YUPELRI is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD, offering patients and clinicians an important therapeutic option that didn’t exist before. We plan to expand access to this drug across multiple countries in our Rest of World (ROW) region. And in just a few examples of helping patients better manage allergies, a growing global health concern, we support an allergic rhinitis application that helps to track symptoms and tailor treatments as well as several websites and social media sites in Europe that help educate patients and their families about allergies and asthma including types of conditions, the progression of the conditions, symptoms and treatment options.

**Expanding Access to Diabetes Treatments**

The number of those living with diabetes is expected to rise to 522 million people by the year 2030. That’s a significant health challenge, but it’s also an economic challenge. An estimated 12%, or $727 billion, of global health expenditures on adults are spent on diabetes-related healthcare. In 2018, Mylan launched the insulin glargine biosimilar Semglee® in the U.K., Croatia and Denmark expanding access to more patients. Mylan’s insulin glargine has received regulatory approval in more than 40 countries.

**Increasing Care for Women**

Mylan’s Women’s Health portfolio spans oncology, hypothyroidism, diabetes and menopause, among other health concerns predominant in women. As part of our commitment to the U.N.’s Every Woman Every Child initiative, Mylan pledged to register our contraceptives portfolio in 80% of Family Planning 2020 target countries (among the poorest countries in the world) by 2020, which we achieved this year. An additional goal is to provide contraceptives to 25 million women and girls in FP2020 countries. Our receipt in 2018 of the first World Health Organization (WHO) Prequalification for medroxyprogesterone acetate, 150 mg (IM DMPA), a generic injectable for Depo-Provera® that provides three months of birth control protection, should help further that effort. Mylan also raises awareness of women’s health concerns in countries like India, where we conducted a workshop for more than 5,000 girls about feminine hygiene, cervical cancer, infections and reproductive complications.

**Serving Patients with Autoimmune Disorders**

In an effort to enhance access to treatment for patients in Europe suffering from chronic diseases such as autoimmune disorders, we launched Hulio®, a biosimilar to AbbVie’s Humira®, in partnership with Fujifilm Kyowa Kirin Biologics. Humira is the world’s best-selling biologic medication, and Hulio offers an important alternative option for patients. The European Commission approval of Hulio applies to all 28 European Union (EU) member countries and the European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein.

---

Working to Improve Heart Health

According to the WHO, cardiovascular diseases are the number one cause of death globally.1 In 2018, we launched Rozor™, a new fixed dose combination of rosvastatin and ezetimibe to improve control of LDL-c (bad cholesterol) in Slovenia, Spain, Czech Republic, Poland and Portugal with more launches planned for 2019. Mylan also added tadalafl tablets USP, 20 mg, the first generic version of the reference listed drug Adcirca® indicated for the treatment of pulmonary arterial hypertension, to our product portfolio in the U.S. We also have approval for this generic in nine other countries currently. To support medical education, we also became a corporate partner of the European Atherosclerosis Society.

Supporting Patients with Digestive Issues

One of the many products in Mylan’s gastroenterology portfolio is Creon®, which we supply in Europe, Canada, Australia, New Zealand and Japan. Creon is used by patients who cannot digest food normally because their pancreas does not make enough enzymes. Some of those who use Creon suffer from pancreatic cancer and may struggle with issues such as malnutrition. Certain cystic fibrosis patient also take Creon. An example of our efforts to support this population is our work in France, where we provide a mobile application to remind children to take their pancreatic enzymes, as well as materials to assist adult cystic fibrosis patients. We also offered master classes to educate healthcare providers on correctly diagnosing and treating pancreatic exocrine insufficiency.

Increasing Choices in Dermatology

Helping patients understand their skin conditions is an important part of our approach to dermatology. This year, we led a variety of activities around the world. In Taiwan and Singapore, Mylan hosted educational workshops on the “atopic march,” the progression from atopic dermatitis to allergic rhinitis and asthma. In China and Thailand, we helped support eczema master classes for more than 1,000 participants. In Sweden, we provide a comprehensive dermatology website to help educate patients on a variety of skin conditions and in Greece, we created a website to assist parents of children with atopic dermatitis. In addition, to support continuing education for dermatologists, Mylan provided a grant to the Interactive Derma Academy which was attended by more than 250 doctors from Europe, South Africa, the Philippines, Thailand and Russia. We also continued our efforts to expand the availability of over-the-counter dermatology products such as our EndWarts® PEN. We currently have marketing approvals for this pen applicator for the self-removal of warts/verrucas in 20 countries and submitted it for approval in several more in 2018.

Innovating to Help Cancer Patients

In 2018, we helped increase access to biosimilars for cancer patients in several areas around the world. In the U.S., the FDA approved our biosimilar Fulphila®, co-developed with Biocon. Fulphila is the first alternative, more affordable treatment option to Neulasta®. This product has been submitted for approval in 47 additional countries. To support those with breast cancer in low- and middle-income countries, we launched Hertraz®, the world’s first biosimilar for trastuzumab, in Senegal, Ivory Coast, Paraguay, Tunisia, Cameroon, Pakistan, Guatemala and Thailand. We also shared our expertise to improve cancer care in places like India, where Mylan provided standardized comprehensive patient care management and chemotherapy training to doctors, nurses and technicians. We also conducted a gap analysis for six targeted district hospitals in India to identify oncology related infrastructure upgrade requirements. As a result, all targeted districts started outpatient departments for cancer, and five out of six now provide chemotherapy treatment centers.

Helping Alzheimer’s Patients

In 2018, Mylan launched a transdermal patch for rivastigmine in the U.S. The generic patch is indicated for the treatment of dementia associated with mild, moderate and severe Alzheimer’s disease and the treatment of mild to moderate dementia associated with Parkinson’s disease. It was originally submitted to the FDA more than five years ago and demonstrates our continued perseverance to serve patients in this area.

1https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
Biosimilars: Unlocking Greater Access to More Affordable Care

Biologics represent the cutting edge of medical science and have become the standard of care for many devastating and debilitating diseases such as cancer, diabetes, rheumatoid arthritis and multiple sclerosis. Due to their complexity, biologics can be expensive and, in some cases, out of reach for patients.

Enter biosimilars. According to regulatory authorities, there are no clinically meaningful differences between a biosimilar and its reference product in terms of safety, purity and potency; the products are expected to offer the same therapeutic benefits.

As a result, the introduction of biosimilars is anticipated to drive healthcare savings. One reason is that of the top 20 costliest drugs in the world, 12 are biologics or insulins. Of those, Mylan has nine biosimilars or insulin products on the market or in our pipeline. By offering an alternative to more costly biologics, Mylan improves access to these important medicines.

Our portfolio includes many of the best-selling biologics globally and focuses primarily on the areas of dermatology, endocrinology, immunology, oncology and ophthalmology. Following years of innovation and R&D, Mylan offers a diverse biosimilars portfolio that includes 20 biosimilars and insulin analogs on the market or in development. Further, Mylan has regulatory approvals for biosimilars in more than 65 countries. That’s a result of our deep experience and ability to develop and manufacture complex products as well as our strong partnerships with companies including Biocon, Momenta, Fujifilm Kyowa Kirin Biologics and Revance.

In addition to launching biosimilars in several European countries and the U.S., Mylan continues to pursue efforts to provide medicines everywhere, including parts of Africa, Asia, Latin America and other emerging markets where medicine is needed most and where access is challenged.

In 2018, Mylan was the first to provide a trastuzumab biosimilar in Guatemala, Thailand and Pakistan.
ADVOCATING ON BEHALF OF BIOSIMILARS

The adoption of biosimilars – when originator biologics are no longer patent-protected – is necessary to ensure patients have continued access to these potentially life-saving medicines. When biosimilars are approved for use and are able to enter the market, competition can reduce medicine prices, meaning more patients have access to this important therapy and health systems can procure more medicine without increasing their budgets.

A key strategy of Mylan’s effort to encourage the adoption of biosimilars is to engage with governments, payers, patients and other healthcare stakeholders around the topic of sustainable access to biologic medicines. We work directly and through trade associations to educate public authorities and payers about key components of a healthy biosimilars market. Collaboration with industry partners and trade associations at local, regional and global levels to raise awareness of the important role these medicines can play in increasing access is core to our health policy work. We maintain leadership roles in many of these associations and use these platforms to encourage adoption of policies that positively impact public health, including the ability to build resilient health systems that position countries to sustainably provide access to medicines for the long term.

Internationally, Mylan and its trade associations engage with organizations such as the WHO on issues of access to biologic medicines. Specifically, work with the WHO has included engaging in debate over a biological qualifier for standardization of biologic naming, the initiation of a pre-qualification pilot for biologic medicines and the WHO Similar Biotherapeutic Product guidance. Mylan’s focus has been on ensuring that global standards and guidelines set by the WHO are focused on ensuring access to high quality biosimilar medicines. To highlight our global mission of access and affordable care and educate about biosimilars, we also launched an international Biosimilars Without Borders campaign.

Despite the number of originator biologics coming off patent and the significant potential for healthcare savings in all parts of the world, there are numerous policy and market-related barriers that can delay biosimilars from entering the market and getting to patients. It is our hope that through strong collaboration and education initiatives biosimilars will continue to gain stakeholder trust and demonstrate the clear impact they have in positively affecting the overall health of the global population.

2018 Achievements

We worked to drive efficient regulatory approval processes and timelines, remove market barriers that unfairly disadvantaged biosimilars and dispel myths that may impede trust and acceptance. Accomplishments included:

- In Europe, Mylan and its trade association participated in multi-stakeholder workshops to develop consensus education materials about biosimilar medicines and engaged in discussions about key topics impacting biosimilar utilization.
- In Australia, Mylan, via its trade association, worked to implement a government-initiated education effort to increase understanding and trust in biosimilar medicines.
- In Canada, Mylan and its trade association engaged with government to develop and implement biosimilar market policies to enhance access.
- In the U.S., we worked with the Centers for Medicare and Medicaid Services to enable more appropriate reimbursement and coding of biosimilars to support more equitable pricing incentives and offered potential solutions via comments to administration proposals that would support increased uptake of biosimilars and decrease the cost of prescription medicines.
Fighting Infectious Diseases

Thanks to modern medications, patients with infectious diseases like HIV/AIDS, hepatitis and tuberculosis who receive the proper care can lead long and healthy lives. However, preventing and diagnosing the diseases and ensuring patients have access to life-saving medications, especially in low- and middle-income countries where the burden is most prevalent, are still global challenges. Mylan takes pride in our history of leadership in this area and continually seeks opportunities to do more.

A Leader in the Battle Against HIV/AIDS

Mylan continues to be a leader in the battle to eliminate HIV/AIDS by providing access to high quality and affordable antiretrovirals (ARVs) in more than 100 countries. We are currently the largest supplier by volume of ARVs to low- and middle-income countries\(^1\) at costs significantly lower than those charged by brand companies.\(^2\)

This year, we’ve made additional strides in offering important new options for patients. We entered into a partnership to supply rapid diagnostic tests for self-testing in low- and middle-income countries and achieved FDA tentative approval for a once-daily, fixed-dose combination of dolutegravir, emtricitabine and tenofovir alafenamide in developing countries. In the U.S., the launches of Symfi\(^3\), Symfi Lo\(^3\), Cimduo\(^3\) and efavirenz support our global commitment to expand access to affordable care.

The Mylan team also drives important conversations among healthcare, community and policy experts to encourage innovative solutions for improving the lives of those living with HIV/AIDS and to end the epidemic. For example, last summer Mylan was a major industry sponsor of the world’s largest HIV/AIDS conference in Amsterdam with the International AIDS Society – the first time ever that a generics pharmaceutical company played this role.

Progress Toward Preventing New Infections

Preventing the transmission of HIV is key to ending the epidemic. In addition to supporting multiple prevention awareness campaigns around the world, we manufacture medicines used for pre-exposure prophylaxis (PrEP), for certain countries, taken by HIV-negative people used to reduce the risk of contracting the virus. We are also the supplier in the U.K. for the National Health Service’s PrEP Impact Trial, the largest oral PrEP study to date.

\(^1\)https://clintonhealthaccess.org/content/uploads/2016/10/CHAI-ARV-Market-Report-2016-.pdf
\(^3\)http://www.unaids.org/en
Building Manufacturing Capacity in Africa

Approximately 20% of all people living with HIV reside in South Africa. The country also accounts for 15% of new infections and 11% of AIDS-related deaths annually.1 In an effort to increase access to life-saving ARVs, Mylan agreed to acquire Ascendis Health’s manufacturing facility in Isando, near Johannesburg, where we plan to create a state-of-the-art manufacturing center for ARVs. In addition, Mylan will train the local team to adopt global standards in critical areas of science, technology and manufacturing processes. The manufacturing center will also create local employment opportunities. Our commitment to the African continent also currently includes a manufacturing facility in Zambia, as well as manufacturing capabilities through local partners in Kenya and Botswana.

Helping the World’s Smallest Patients

As any caregiver knows, getting babies to take medication can be extremely difficult, especially if it is a bitter-tasting syrup. To help address this issue, Mylan developed a sweet-tasting, pediatric-friendly option for HIV-positive infants that can be dissolved in a child’s water or food as part of their HIV regimen. In 2018, we received tentative FDA approval for first-ever Lopinavir/Ritonavir 40mg/10mg oral granules, a pediatric-friendly ARV for HIV-positive infants. We also plan to submit 4 in 1 oral granules to the FDA for approval through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) program. If approved, this product will be another first of its kind for children living with HIV.

Adding Convenience and Affordability Through Multi-Month Packs

Mylan continues to support the use of multi-month packs for HIV patients. These packs are cheaper on a per-pill basis and more convenient, reducing the need for patients to travel for prescription refills. In its 2018 guidance to countries, PEPFAR identified adoption of multi-month prescriptions as part of the minimum requirement for continued PEPFAR support.

Bringing Diagnostics to Low- and Middle-Income Countries

Making diagnostics more available to patients is essential to moving toward the Joint United Nations Programme on HIV/AIDS (UNAIDS) treatment targets of 90/90/90 (see chart below).

Our agreement with Atomo Diagnostics to commercialize Mylan’s first-ever HIV self-test in low- and middle-income countries is a critical step in helping hard-to-reach populations know their HIV status. The test allows individuals to screen themselves in their own homes with a single drop of blood obtained from a fingertip.

Mylan Supports the UNAIDS Targets for HIV:2

- By 2020, 90% of all people living with HIV will know their HIV status
- By 2020, 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy
- By 2020, 90% of all people receiving antiretroviral therapy will have viral suppression

2http://www.unaids.org/en/resources/909090
Focusing on Awareness, Prevention and Treatment for Hepatitis

One of the major barriers to effectively treating hepatitis B and C around the world is that many patients are unaware they have the disease due to limited education about the condition and lack of access to quality screenings. To help combat this problem, Mylan launched multiple campaigns in some of the hardest-hit countries, including India, Egypt, Thailand and the Philippines. In addition to offering free screenings and consultations, the campaigns promote the importance of screening, disease management, treatment options and the steps needed to increase a patient’s adherence to treatment. Mylan has also developed new partnerships such as those with the governments of Burkina Faso, Ivory Coast and Cameroon to launch hepatitis B and C programs which bundle treatment and diagnostics, facilitate screening programs and build patient and provider awareness.

Moving forward, we hope to significantly increase the number of patients reached by Mylan’s products by participating in expanded government programs. We will also continue working with multilateral agencies such as the United Nations Development Programme and UNAIDS. To further support access to hepatitis C (HCV) treatment, Mylan has applied for WHO prequalification for a number of HCV direct-acting antivirals and is awaiting approval.

Partnering to Treat Tuberculosis

In September 2018, the U.N. held the first-ever High-Level Meeting for Tuberculosis. This established tuberculosis as a global priority, garnering commitments from all over the world to scale up programs to fight tuberculosis (TB), which kills more people annually than AIDS.

Drug resistance poses a serious challenge to treating TB. South Africa and India are considered by the World Health Organization (WHO) as among the highest-burden countries for multi-drug resistant tuberculosis (MDR-TB) and TB/HIV co-infection, with more than 150,000 estimated new cases of MDR-TB/rifampicin-resistant TB in 2015 alone.1

To provide more MDR-TB patients with access to treatment, Mylan has been granted a license from Otsuka Pharmaceuticals to prioritize access to Deltyba® in South Africa and India. We further agreed to extend commercial rights and registration responsibilities to many other high MDR-TB burden countries. Looking forward, Mylan is assessing ways to reduce the cost of treatment to make it more accessible. We are also exploring additional partnerships to further support the development and delivery of better, faster-acting and affordable TB treatments.

Fighting the Flu Virus

In Europe alone, seasonal influenza causes between 4 and 50 million symptomatic cases each year.3 To achieve a higher level of protection against multiple strains of the virus, in 2018, Mylan launched Influvac® Tetra in Europe, Australia and New Zealand. In addition, we are sponsoring a European initiative with other partners to increase flu awareness and educate the public on the importance of vaccinations.

---

2https://extranet.who.int/prequal/content/prequalified-lists/medicines, as of 2.1.19

In 2018, Mylan provided hepatitis B and C treatments for more than 350,000 patients in low- and middle-income countries and supported free hepatitis screenings in countries such as Egypt and India.

Mylan is among the leaders in products listed on the WHO list of prequalified products, with 88.2

Prequalification allows for U.N. procurement and accelerated registration processes in low- and middle-income countries.

In 2018, Mylan became the first company to receive WHO prequalification for fluocytosine 500 mg, an orphan drug used for the treatment of cryptococcal meningitis.
INNOVATING FOR ACCESS

At Mylan, we invest in science and believe that innovation is key to expanding access to medicine. We continually review our product portfolio, manufacturing network and supply chain to ensure our products help address unmet needs while supporting our mission. For these reasons, it is not uncommon for us to be among the first to manufacture difficult-to-make generic versions of drugs.

Our work to develop complex generics such as glatiramer acetate for the treatment of multiple sclerosis and Wixela™ InHub™, a generic to the brand-name respiratory drug Advair®, are two such examples. We also place a strong emphasis on the delivery of complex injectables and biosimilars. Two examples include Fulphila, a biosimilar to Neulasta®, for the treatment of chemotherapy-induced febrile neutropenia (fever in patients with low white blood cell counts) and Hulio, a biosimilar to Humira®, often used by patients diagnosed with rheumatoid arthritis, Crohn’s disease and psoriasis, among other conditions.

2018 was a year of significant scientific achievement for Mylan. Many years of work culminated in our ability to expand our portfolio to treat non-communicable conditions such as diabetes, cancer and a variety of women’s health concerns along with medicine to treat infectious diseases such as tuberculosis, hepatitis, HIV/AIDS and malaria.

In 2018 we:
- surpassed our goal of 500 regulatory filings around the globe,
- received more than 900 global product approvals, and
- completed 11 drug master filings. A drug master file (DMF) contains detailed information on a new API molecule that will be used in a new Mylan medicine.

In 2018, Mylan completed 168 market submissions in more than 120 countries. This included 98 products in emerging and expansion markets.

YUPELRI (revefenacin) inhalation solution, a new chemical entity (NCE) and novel drug approved in 2018, is one example of how we are further extending our ability to impact patient outreach, prescription compliance and access. The approval of YUPELRI represents a key milestone in advancing and expanding our scientific expertise regarding respiratory care. YUPELRI provides Chronic Obstructive Pulmonary Disease (COPD) patients in the U.S. with access to a nebulized, long-acting muscarinic antagonist (LAMA) therapy that offers consistent 24-hour lung function improvement with the convenience of once-daily dosing delivered through any standard jet nebulizer.

YUPELRI was developed in collaboration with Theravance Biopharma, and is just one example of the important role collaboration can play in increasing access. Additional Mylan partners in 2018 included: Biocon, Fujifilm Kyowa Kirin Biologics, Momenta and Pfizer, to name a few.

In addition to new chemical entities, Mylan R&D is also focusing on developing new delivery devices. In 2019, while we continue our core generic drug development, we will be leveraging our internal capability to develop additional complex and differentiated products. Focus areas will include not only devices, but biosimilars, complex injectables, topicals and other important products as we continue to identify unmet needs and create solutions to address them.

Rest of World*
600 products in development
1,620 products pending approval

Europe*
200 products in development
730 products pending approval

North America*
340 products in development
220 products pending approval

*Products taken from internal data and rounded
OUR RESPONSE TO THE U.S. OPIOID EPIDEMIC

Over the course of Mylan’s history, we have worked to help address some of the world’s most pressing public health problems. The ongoing opioid crisis is no exception. Mylan fully recognizes the scope of this issue and is committed to doing our part to help in the fight against opioid addiction, abuse and misuse.

Regarding Mylan’s presence in the U.S. opioid market, the company has a limited role. We supply approximately 1.1% of opioid-containing drug products sold, according to 2017 IMS data. Mylan’s opioid portfolio consists of generic products and one branded product that is not part of the national discussion on opioids because it is an intravenous anesthesia medicine administered only by healthcare professionals in a surgery-center setting for which patients do not receive prescriptions. Mylan is not promoting or marketing any of its opioid products.

However, given our leadership position within the generic pharmaceutical industry in particular and our extensive scientific capabilities, we are committed to finding ways to be a part of the long-term solution to this challenge. In 2014, Mylan launched a generic, injectable, single-vial version of naloxone, a product that is indicated for the complete or partial reversal of opioid depression induced by some natural and synthetic opioids, as well as for diagnosis of suspected or known acute opioid over-dosage. In the summer of 2016, Mylan launched a multiple-vial version of its generic naloxone injectable, thereby increasing supply for customers, physicians and other providers seeking additional inventory of this important therapy. Mylan's injectable naloxone products are primarily used by hospitals. Today, Mylan's naloxone presentations are the lowest price options in the overall naloxone market, which includes auto-injectors and prefilled syringes. Mylan stands ready to continue to provide reliable supply and access to this important product, including through a commitment to develop an auto-injector drug-device combination for naloxone.

In April 2018, the company announced plans to leverage its world-class scientific platform to develop a novel delivery for meloxicam, a non-opioid pain medication, and we remain committed to bringing this product to market. Promoting the development of non-opioid pain treatments is one of the many areas the FDA is focused on as part of its efforts to address this growing public health problem.

Mylan’s portfolio includes the fentanyl transdermal system, which is a generic version of Johnson & Johnson’s branded fentanyl patch product, Duragesic™. Mylan’s fentanyl transdermal system is indicated for the management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative options are inadequate. Mylan’s generic patches utilize a matrix technology in which the fentanyl is incorporated into the adhesive layer of the patch. Accordingly, Mylan’s patches have no drug reservoir containing fentanyl gel. Mylan’s matrix patches are among the products containing the least amount of fentanyl needed to deliver the labeled dose. At the time of its approval, Mylan’s matrix technology design represented an important innovation for the product.

Mylan recognizes that fentanyl is a big part of the national opioid crisis. Importantly, however, lawful fentanyl products such as Mylan’s fentanyl transdermal system have been broadly acknowledged by federal authorities as not being responsible for the current fentanyl crisis. In its 2017 National Drug Threat Assessment Summary, the U.S. Drug Enforcement Administration concluded that “illicitly-produced fentanyl is responsible for the current fentanyl epidemic.” Mylan further recognizes that there has been focus on payments made by drug manufacturers to third-party advocacy groups and professional societies. Former Senator McCaskill issued a report on February 15, 2018, on this topic that positively differentiated Mylan, finding that the company is “[a]t the other end of the spectrum” from the other companies whose payments were examined because Mylan made only de minimis payments, and to only one of the 14 third parties cited in the report. Moreover, Mylan continues to cooperate with separately disclosed government inquiries that it has received.

Mylan is also fighting the opioid epidemic by taking seriously the need to safeguard against diversion and abuse of opioids. We have internal practices designed to detect suspicious orders and prevent the sale of opioid-containing products where there may be a risk of diversion.

We remain dedicated to working with key stakeholders across the spectrum of opioid-related issues to continue to identify avenues to help bring an end to this public health challenge.
ENSURING QUALITY AND SAFETY ARE OUR HIGHEST PRIORITIES

We know that what we do directly impacts the health and well-being of patients. As a result, protecting patients and consumer health by ensuring the quality and safety of our products is at the heart of how we operate across our network. From product development to making or sourcing raw materials to producing finished dosage forms, every step of our development, manufacturing and monitoring processes is grounded in this commitment.

Developing Quality Products

Quality begins at product development. We employ a team of highly-trained scientists and technical professionals with extensive experience in the pharmaceutical industry to develop each product formulation and to identify the specific processes and technologies used to manufacture our products. All our applications are subject to a robust regulatory review before a product can be brought to market. We monitor the performance of our products after approval and identify and implement any changes necessary to ensure quality. Significant changes also are subject to review by regulatory agencies.

Ensuring Product Safety and Preventing Risk

Our Pharmacovigilance (PV) program, coupled with a global policy on product safety, guides Mylan’s approach to ensuring patient care and safety in relation to the use of our marketed products. In line with applicable global legislation, we have a cross-functional team of medical and scientific professionals that support a global pharmacovigilance system that reports our risk/benefit assessments to global health authorities.

Our Product Safety and Risk Management (PSRM) department is a key component of our program and is responsible for conducting internal and external audits along with ensuring that the personal health information of those participating in our clinical trials is carefully safeguarded. It is subject to external audits and inspections from health authorities around the globe.

Mylan’s Corporate Product Safety Committee provides a forum for the periodic and ad hoc evaluation of newly emerging safety information regarding our products. Potential safety signals are assessed and evaluated through our corporate safety governance structure and new information is communicated in a timely manner to healthcare professionals, patients and health authorities. Mylan currently has more than 300 risk management plans and associated interventional measures designed to ensure all of Mylan’s products are used safely and effectively.

We conduct training that complements Mylan’s policy on Pharmacovigilance Training Standards which defines training curriculum, frequency, effectiveness measurements and documentation and other requirements. PSRM employees are assigned professional development training courses based on individual experience. In 2018, we completed 25 PV audits and submitted more than 1,600 safety reports.

Mylan partnered with the European Parliament and Council of Ministers to develop its current pharmacovigilance legislation. The legislation led to the implementation of Good Pharmacovigilance Practice, or GVP, within the European Union. We also worked on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) committee that redefined electronic standards for collecting and reporting safety data worldwide.

Our active support to develop harmonized legislation and guidelines helped facilitate smooth implementation for both the regulatory authorities and the pharmaceutical industry with beneficial impact for the protection of public health.

Mylan has company-wide policies and management procedures to ensure product quality and safety across our operations.
Quality Manufacturing

We are committed to maintaining high standards at all our facilities and ensure regular, comprehensive oversight of our entire manufacturing network. In addition to Good Manufacturing Practices (GMP), we apply all other applicable quality guidelines and practices, including, for example: Eudralex, Falsified Medicines Directive, ICH Quality Guidelines, WHO GMP, Food and Drug Administration Safety and Innovation Act (FDASIA) and the EU Excipient Risk Assessment for ascertaining GMP for excipients of medicinal products for human use. We use a Regulatory Intelligence and Knowledge Management Dissemination Program to better inform, evaluate and implement regulatory updates, industry trends and internal knowledge.

Risk assessment is central to our approach to ensuring quality in our facilities around the world. We promote regular self-inspection of our sites and conduct annual audits. Our Quality Council Program drives appropriate quality management action by tracking quality issues; analyzing metrics to identify trends, issues and risks; examining key performance indicators; and providing clear and accurate data analysis. In 2018, we expanded our self-inspection auditor certification program across all of our operations to further strengthen site self-regulation.

Externally, we apply an audit schedule based on business prioritization, cyclical audit requirements of facilities, key launches and historical regulatory inspection performance. In 2018, we completed 610 quality and GMP audits at our suppliers’ and 41 quality and GMP audits at our own facilities.

Training for Continuous Improvement

Our Global Operations Training program is a harmonized global learning process that provides consistent and effective training to assure access to and delivery of knowledge to Mylan operations personnel. This program continues to provide oversight and governance to coordinate and standardize training requirements, content, techniques and training delivery methods to continually strengthen our corporate learning culture while ensuring that role-specific and periodic GMP training programs are compliant with regulatory requirements both regionally and globally.

Maintaining a High Quality Supply Chain

Our global supply chain is strategically designed to support the continued growth of our business and to protect the quality and safety of our diverse and increasingly complex products. Approximately three years ago, Mylan initiated a program to implement state-of-the-art technology for supply chain planning and building new competencies. Today, the majority of the program is deployed and Mylan is more closely connected across its global operations. This enables us to update and share information in real time, allowing us to leverage capacities and resources across key functions such as commercial, warehousing and manufacturing. The new technology will support more optimal planning along our entire supply chain. We hope this will help us not only better serve customers and patients in the future but also bolster inventory management and logistics.

Working with Health Authorities

We constantly review our products, processes and facilities throughout our network and work closely with external health authorities to ensure transparency with emerging information, including shortages, adverse event reporting of other manufacturers’ products, development of new scientific and testing criteria and evolving regulatory and manufacturing expectations everywhere we operate. We continuously learn from these interactions as scientific, technology and regulatory expectations continue to evolve.

In 2018, global health authorities conducted OVER 120 REGULATORY INSPECTIONS of our more than 40 manufacturing facilities around the world. Please see Mylan’s 2018 Annual Report on Form 10-K for more information.
Fighting Falsified Medicine
Quality and product safety expectations are escalating globally from a variety of stakeholders. There is now a greater emphasis on companies taking responsibility for their supply chains, data integrity and quality assurance, priorities Mylan has embraced for many years.

Falsified medicine – medicine that is sold as authorized, authentic medicine but in fact contains ingredients of bad or toxic quality or dosage – continues to be an issue for the pharmaceutical industry. Beginning in 2010 and continuing through 2018, we made significant investments in packaging and information technology to enhance product safety. By lowering the likelihood that falsified products will enter our supply chain, we are helping ensure access to high quality medicine. Global policies have been established to govern validation, operations and product security. New and updated procedures have also been implemented across all manufacturing sites to drive consistency in packaging, management and distribution of serialized product. Among these are processes to track and trace serialized products. An internal product safety group helps monitor the supply chain to help ensure it is not breached.

In 2019, we will continue to build out our technology, aggregation and distribution capabilities designed to comply with the requirements of the European Union Falsified Medicine Directives. We’ll also continue to work with our U.S. suppliers to verify returns of serialized product. Lastly, we’ll continue to build out our aggregation and distribution capabilities and encourage our supply chain partners to share serialized product data.

Serialization is a process that helps companies obtain valuable information about the products they sell, and where they are made and shipped. It is fueled by myriad government regulations that require pharmaceutical companies to track their products along the supply chain and verify their authenticity. The goal of serialization is to ensure that medicines reaching consumers are not counterfeit, stolen or contaminated.

In the U.S. all products packaged on or after Nov. 27, 2018, must be serialized under the Drug Supply Chain Security Act; a deadline of Feb. 9, 2019, was set for the European Union under the Falsified Medicines Directive. Our quality, regulatory and serialization teams are also ensuring that similar requirements for other countries are met. Mylan is working closely with industry groups such as the RxGPS Alliance, a group of multinational pharmaceutical supply chain stakeholders who have a common interest in advancing global alignment of drug serialization and tracing requirements to harmonize various standards among countries.

Serialization efforts include technology that places a serialization mark, known as a 2D data matrix, on products. In addition, Mylan works with contract manufacturers to ensure the products they make for us also include this identifying mark. Eventually, this serialization process will lead to aggregation, which places a unique code on shippers of our products. This code will associate data for each individual product packaged within it.

Once the 2D matrices are added, our work continues. The large amounts of data created by serialization must be maintained and processes must be established so that Mylan can identify and manage procedures associated with individual units like product picking, packing, shipping, sampling, returns and destructions.
**Addressing Supply Constraints**

Mylan understands and appreciates the importance for individuals with life-threatening allergies to have immediate access to epinephrine auto-injectors. In 2018, the manufacturer of EpiPen® (epinephrine injection, USP) 0.3mg and EpiPen Jr® (epinephrine injection, USP) 0.15mg Auto-Injectors experienced interruptions in production.

As the distributor, Mylan has taken a number of steps to alleviate the situation, including:

- expediting shipments upon receipt,
- working closely with the manufacturer to stay informed of anticipated shipments and maintaining regular dialogue with health authorities to provide frequent updates on supply status,
- establishing a dedicated Customer Relations team to successfully find the product for patients and caregivers who need assistance, and
- coordinating with the manufacturer and health authorities on extending the expiration dates of specific lots of EpiPen® 0.3mg Auto-Injectors.

We are continuing to collaborate closely with the manufacturer to support their efforts to increase production and resolve the situation.

**Supporting Appropriate Use of Medications**

Helping patients use medicines appropriately and adhere to prescriptions are crucial factors in improving health and well-being around the world. Mylan promotes the appropriate use of medicines and has several initiatives aimed at educating patients on medical conditions and ways to better manage them.

We support online portals, websites and mobile applications that offer features ranging from tracking symptoms to reminding patients about refilling prescriptions. In addition, some digital solutions provide real-time guidance for healthcare providers to help them understand a patient’s overall status.

Mylan also supports individual dose dispensing across several European countries to increase therapeutic adherence and reduce medication errors, which is particularly important for elderly patients taking multiple medications. Dose dispensing not only helps an individual patient use medication correctly, it also assists caretakers and healthcare professionals in managing medications more effectively.

In addition, Mylan continues to adapt its packaging to include symbols and pictograms that illustrate dosage schedules to make it easier for patients to take the right doses of medicines at the right time.

**AUTOMATED DOSE DISPENSING**

Automated dose dispensing (ADD) is the dispensing of one or more different medicinal products into a chain of pouches. One pouch contains either one, some or all units of medicine an individual patient needs to take at a particular date and time.

For information on our pricing model, see page 61.
Conducting Responsible Clinical Research

Mylan conducts clinical trials in many regions of the world as part of making treatments available to patients. Clinical investigators conduct careful screening and selection of patients according to criteria outlined in Mylan clinical study protocols, which are developed for every clinical trial.

At the center of our clinical investigations is our Quality Management System (QMS). It includes procedures that address internal processes associated with drug development as well as processes for overseeing and auditing outsourced activities completed by our vendor partners. In 2018, 59 GCP audits were performed across our own and partner sites.

The QMS also includes detailed procedures regarding the development, review, approval, implementation and confirmation of the informed consent process. Informed consent documents are written in a manner that allows potential trial participants, regardless of reading skills and local language, the ability to make an informed decision, considering risks and benefits of trial participation. Local ethics committees review and approve informed consent forms prior to patient participation in a clinical study. The clinical investigator ensures that patients understand the informed consent document prior to participation in the clinical study. The QMS further provides guidance on assessing risks associated with the various aspects of clinical development, such as study design, vendor selection, site selection and patient populations. Procedures in the QMS also address the publishing of Mylan clinical trial data in publicly-accessible registries, as required by global regulations to promote transparency.

Mylan’s governance councils and quality committees oversee the conduct of clinical trials and partner with internal and external experts and investigational sites to promote patient safety and data integrity across our clinical development programs. In addition, we use quality councils, governance boards and independent data monitoring committees when appropriate to support quality, safety and protection of participants in our clinical development programs.

We do not conduct animal testing unless it is required by national regulation. Mylan is committed to the “3 R” approach (Replacement, Reduction and Refinement) with respect to ethical animal testing.

Facilities performing animal testing on our behalf are required to comply with regional scientific procedures for laboratory animal science. These facilities use and/or are approved by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). Mylan’s Global Operations Audit team performs regular audits on all parties to ensure compliance.
Better Employee Health

Key 2018 Accomplishments

• Received an 88% global response rate to our global employee engagement survey with 80% of employees saying they are proud to work at Mylan

• Reached a 97% integration rate of our employees into one global source of workforce information, allowing for enhanced data analytics, consistent reporting of talent data and improved manager access to data

Current Challenges

• Striving to achieve an even more diverse and inclusive workplace to gain broader perspectives, drive innovation and support our efforts to attract and retain the right talent for our business today and in the future

Future Opportunities

• Implement action plans resulting from the global employee engagement survey at every site to ensure Mylan remains a great place to work

• Continue to build comprehensive succession plans for critical roles across geographies and create future bench strength
Mylan impacts the lives of millions of patients each year. Our passionate and talented global workforce of approximately 35,000 is fundamental in bringing our mission to life. Around the globe, our people understand how they as individuals are critical to expanding access to high quality medicine. In return, we offer outstanding benefits and compensation and partner with them to plan for their continued professional development and growth.

**OUR PROGRESS IN 2018**

**Global Integration**
Successfully integrating employees from acquisitions gives Mylan the opportunity to deepen our talent pool, further strengthen our culture and take new approaches to how we do business. Last year we completed the integration of most employees from the Meda and DPT Laboratories acquisitions into many of our global processes and systems. Now, 97% of our employees are operating under one HR information system. As an integrated organization, this centralized source of workforce information makes it easier to review data holistically so we can make informed decisions that benefit the business and our people everywhere.

**Engaging Our Employees**
We understand that employees who know they are being heard are more likely to feel connected, engaged and motivated to do their best work. Their insights and experiences are valuable as Mylan continues to evolve. That’s why in 2018, we initiated a global employee engagement survey to better understand the needs, insights and unique experiences of our employees. The survey was also an opportunity to collect input from employees who joined Mylan as a result of acquisitions.

The results affirmed that our people are committed to our organization and mission. When asked, 70% said they would go above and beyond in their roles to support the company. This global engagement score (70%) is based on employees’ satisfaction, interest in continuing to work at Mylan, pride in the company and willingness to recommend Mylan as a great place to work.

With this survey also came more than 40,000 free-response comments. Anonymous feedback was circulated to our leadership team for additional review, consideration and discussion.

**Employee Survey Highlights**

- 81% see a clear link between their work and the company’s mission
- 86% think Mylan sets clear performance standards for quality
- 90% agree that Mylan supports ethical behavior and practices
- 75% say they are extremely satisfied with Mylan as a place to work

Mylan surpassed the average first-year participation rate of comparable companies (78%), with more than 88% of employees participating in the survey globally.

*IBM Watson*

Based on the survey, employee development, process efficiency and two-way communication were identified as priorities for global action planning in 2019. Leaders at all levels of the organization held meetings in 2018 to review and discuss their teams’ results. Employee feedback will be used to design action plans for more than 100 sites in all. Progress in 2019 will be measured using smaller pulse surveys.
BUILDING AND REWARDING TALENT

How a company manages its people plays a crucial role in recruitment and retention. Mylan has a strong track record for attracting and retaining high performers in their fields. In the coming year, we will continue to find ways to expand our talent pool with individuals who are a good fit for Mylan and develop new programs that allow us to reward our people and ensure we are helping them achieve their goals.

Recruitment

Mylan continues to be an attractive employer globally and last year we hired approximately 4,000 people. Attracting and retaining talent early in a career is foundational to our recruiting approach. In 2018, we offered student opportunities in which more than 230 participated worldwide. Students received feedback and opportunities to network.

Learning and Development

Learning never stops at Mylan. We give employees the tools they need to reach their full potential and support continuous learning. We strongly believe, however, that some of the best learning happens when employees step out of their comfort zones to grow professionally and personally. Through informal and formal mentorship and coaching, employees are challenged to learn and grow. We also use a learning management system, MyUniversity, for online education.

In 2018, our leadership team began work on a global framework designed to enhance professional growth and development. Programs currently exist at a regional level; our M-EDGE and M-LEAD offerings in India are good examples. M-EDGE gave more than 3,000 employees training on excellence, communication and collaboration skills, while M-LEAD helped future leaders further develop emotional intelligence, understand the importance of teamwork and define their personal brand. Approximately 240 employees participated in M-LEAD in 2018.

To help our managers enhance their leadership skills and develop their teams, in 2018 Mylan designed training to help them deliver quality feedback. Work will continue in 2019 with this group to refine their coaching skills. Throughout 2019, all employees and managers will be encouraged to have open, honest conversations to set development goals that support continued growth.

TALENT PRINCIPLES

- Hiring with rigor is a must. We connect with the right talent every time. We look at internal talent and encourage unconventional career moves.
- Building talent is the responsibility of every leader.
- We invest management energy in assessing talent and potential.
- Employees own their careers.
- Professional development is required for everyone – not just a select few.
- Successors are identified for all critical roles.
- Diverse perspectives drive innovation.

Number of course completions in MyUniversity in 2018: 2.9 million

Please see Appendix for additional data.
Performance Management

We know a strong focus on performance sustains our company and motivates our workforce. It’s why employees set annual performance objectives that align with key business priorities.

Performance is based not only on what the employee achieves but how they achieve it in relation to Mylan’s Leadership Expectations of Lead, Learn, Teach and Perform with the right Attitude. These Leadership Expectations provide clear guidance for what is expected of our people and in fact, when asked in the engagement survey, 88% said they have a clear understanding of what is expected of them.

Compensation

We have a competitive compensation framework that balances short- and long-term incentives to effectively retain and reward talent. It includes performance-based rewards in addition to base salary, both of which are designed to incent the continued development of our business, recognize achievements, create shareholder value and encourage behaviors expected of leaders. During the annual compensation review process, Mylan evaluates total compensation and employee performance. This includes review and remediation of discrepancies by gender, if needed. Looking ahead, we will continue to ensure our compensation programs are competitive, harmonized and fair.

Succession Planning

With the support of the Mylan Board, our leadership team began formalizing its succession planning with regard to critical global positions. Our work in 2018 included a review of key roles to be included in succession planning and a review by senior leaders of potential internal candidates. Succession planning is ongoing and throughout 2019, we’ll continue to identify successors and create development plans that will position these candidates for success in their next roles at Mylan.

Employee Recognition

Planning began in 2018 to expand global programs that celebrate employee accomplishments. In 2018, we introduced Mylstones, a Mylan program that recognizes employees celebrating major service anniversaries worldwide. Additionally, there are a number of regional recognition efforts of which we are proud. In India, programs range from appreciation letters from leaders to formal recognition of work that complements Mylan’s mission and values. In Europe, our leadership team sponsors the BRAVO (Building Results by Adding Value to Others) Award each year. This award is designed to share best practices from different departments and recognize successful initiatives.

In 2019, we will implement a global recognition initiative that puts the spotlight on employees’ achievements and success. Employees will be encouraged to nominate peers or teams. Those recognized will receive meaningful rewards and incentives.

Adapting Our Workforce

As part of our efforts to complete the integration of employees from acquired businesses, we continued our work to ensure we had the right people in the right roles at the right time. We also took very seriously the learnings from inspections of our facilities by the FDA and other health authorities and, where necessary, adjusted staffing to better complement our manufacturing needs. Employees impacted by restructuring efforts were offered severance packages typically exceeding legally required severance pay and benefits, including outplacement assistance to help bridge them to subsequent employment, and always in compliance with local laws and practices.
INVESTING IN EMPLOYEE WELL-BEING

As a healthcare company, we believe a healthy lifestyle can significantly impact the well-being of our people. We offer a variety of generous benefits that are customized to the needs of our employees around the globe. These may include retirement plans, health insurance, childcare, preventive health screenings, immunizations and other benefits that enable our people to take charge of their personal and financial well-being.

Well-Being Around the Globe

It’s important our people remain healthy and at their best. We encourage employees to participate in our flu vaccination effort and take full advantage of employee assistance programs that provide support to employees facing emotional challenges.

Mylan provides a number of well-being benefits for our employees in India including annual health checkups, free meals and transportation, and subsidized interest rates for housing. For our colleagues in Europe, while activities vary by country, we offer a variety of health and wellness activities including bike to work schemes, annual health checks, family days for employees and subsidized gym memberships among others. In the U.S., Mylan offers a wellness program that focuses on helping employees improve their physical activity and nutrition and relieve stress. We also encouraged employees to take charge of their financial wellness through our 401(k) Plan, Health Savings Account and a 529 College Savings Plan. In 2018, we expanded or introduced additional benefits in the U.S., including enhancements to bereavement time off, vacation, parental leave and assisted fertilization.

While approaches may vary from location to location, Mylan is working with employees to identify ways we can help our people balance life priorities and improve workplace flexibility. Technology is a great start. It enables employees to use their work time efficiently, connecting, collaborating and communicating with colleagues without the need to travel and spend time away from family and loved ones.

CREATING A WELCOMING WORKPLACE

Diversity and Inclusion

Differing perspectives and life experiences make our business stronger. Our people reflect the communities where we work as well as the populations we serve. We are committed to fostering a culture of inclusion, integrity, dignity and mutual respect. We are an equal opportunity employer that embraces what makes our people unique.

Discrimination, harassment of any kind and retaliation are strictly prohibited. We educate employees on our equal employment opportunity and nondiscrimination policies as part of our mandatory annual Code of Business Conduct and Ethics training.

When asked in the 2018 employee engagement survey, 79% of employees said they fit well into Mylan’s culture.

Recognizing Freedom of Association

Mylan recognizes and respects the rights of employees to have access to representation and collective bargaining. Around the world, we have a significant number of employees in manufacturing, commercial and corporate functions who are represented and covered by collective agreements. We engage with employee representatives globally and strive to maintain productive relationships with them and all employees.

“I firmly believe it’s not enough for just women to help women. We need our fathers, brothers and sons to respect and empower women as equals if the world is to make any meaningful progress.”

– Heather Bresch

Please see Appendix for additional data.
SAFETY IS EVERYONE’S RESPONSIBILITY

We are committed to the safety of all employees and believe that everyone must do their part to promote a work environment in which we play a role in our safety and that of our colleagues. Mylan’s Global Health and Safety Policy, along with our Environmental, Health and Safety (EHS) Management System and Technical Standards, set minimum requirements for health and safety programs and practices.

We have rigorous programs in place to ensure a safe and healthy workplace for all Mylan employees, contractors and visitors. Examples include but are not limited to emergency response, incident prevention, contractor safety, occupational toxicology, industrial hygiene, process safety, EHS training and regulatory compliance.

In 2018, we had seven new sites become OHSAS (Occupational Health and Safety Assessment Series) 18001 certified, bringing our total to 12 (approximately 27%). Additionally, two of our India API locations received the Five Star Occupational Health and Safety Designation and the Sword of Honor from the British Safety Council, one of the world’s leading health and safety organizations.

We cultivate an environment that encourages our people to speak up and play an active role in making workplace safety a priority. Our injury-prevention strategy promotes the identification and correction of potential hazards and the Incident Prevention Opportunity (IPO) Program encourages employees to identify potential hazards and act to correct them as soon as possible. Our Serious and Fatal Incident Prevention (SFIP) Program identifies potential situations that could create a more severe outcome and proactively addresses these conditions with effective controls.

Preparedness Counts

Incidents and natural disasters can happen anywhere and at any moment. We strive to keep our facilities resilient and secure, especially those vulnerable to natural disaster. Risk engineering and emergency response planning are vital components of our EHS programs and across our operations we have well-trained emergency response teams and technology to respond quickly should an incident occur. When a natural disaster strikes, Mylan and its partners are at the ready to protect our sites and resume production as soon as possible, always keeping safety top of mind.

Driving Safely

Road injury is one of the top 10 causes of death globally and distracted driving is one of the leading causes of vehicle incidents. In 2018, we conducted campaigns aimed at reducing distracted driving for our commercial and manufacturing employees in North America and our European commercial teams. Additionally, in India, we launched a “No Helmet, No Parking” initiative in order to stress the importance of wearing a helmet for employees who drive motorcycles to work. Lastly, we launched a new EHS mobile app to our commercial teams in North America and across Europe. The app provides teams easy access to EHS information such as product safety data sheets, our incident reporting system and Mylan’s 24/7 security hotline. Along with the launch of the app, we upgraded our EHS Incident Management System to better track automobile and injury related incidents within our commercial teams. In 2019, we are planning to launch the mobile app to our commercial teams in our ROW region.

Mylan’s Global Days Away, Restricted or Transferred (DART) Rate in 2018

0.39 cases per 100 employees

This is 61% below industry average*

03

Better Environmental Health

Key 2018 Accomplishments
• Committed to the AMR Industry Alliance’s Common Antibiotic Manufacturing Framework
• Increased our CDP Climate Change disclosure score and submitted our first CDP Water Security response

Current Challenges
• Balancing quality product manufacturing requirements with efforts to reduce our environmental impact
• Finding ways to reduce water consumption and increase reuse while maintaining the integrity and quality of our manufacturing process

Future Opportunities
• Continuing to promote site-based initiatives to reduce our impact on natural resources
• Future goal setting and science-based target setting
Strong Environmental Principles

Responsible environmental stewardship and promoting safe, sustainable operations is a priority for Mylan. Guided by our Global Environmental Policy and the principles in our companywide Global Environmental, Health and Safety (EHS) Management System, our teams work systematically and continuously to identify ways to minimize our impact on the environment by improving energy and water usage, reducing greenhouse gas emissions and improving waste management.

An Integrated Approach to Environmental Management

Our Global EHS function is integrated across the organization and reports into the Chief Operating Officer, who chairs Mylan’s EHS Governance Committee and oversees EHS programs, performance and initiatives. Working collaboratively with operations and business unit leaders, the EHS team leverages technical expertise across multiple disciplines, including environmental management, health and safety, industrial hygiene, occupational toxicology, training, process safety and systems.

Mylan’s Global EHS Management System is based on companywide principles that provide a framework of performance expectations with respect to our employees and external partners. Our technical standards establish global minimum operating requirements for a variety of safety and environmental activities. Implementing these standards helps ensure compliance with applicable regulations in the countries where we operate, in addition to filling gaps where certain regulations may not exist and driving continuous improvement.

We monitor and track many elements of our environmental performance allowing us to manage data, oversee results and identify risks and opportunities. We routinely conduct assessments and on-site audits, including reviews of our data, systems and programs. Twenty – or approximately 45% – of our manufacturing sites are ISO 14001 certified for environmental management systems.

Conserving Water and Managing Wastewater

Water is an essential component of pharmaceutical manufacturing. A high quality water supply is critical to ensuring that all aspects of production meet Mylan standards. We recognize that water is a scarce resource in some of the communities where we live and work and are committed to working proactively to protect water resources and continue to improve our water management practices and systems. Our teams work to identify opportunities to improve water management within our highly regulated industry, which often presents many restrictions and limitations related to items such as reuse of water in production.

Wastewater from all of Mylan’s operations undergoes treatment prior to discharge to the environment and, in India, multiple sites apply zero liquid discharge technology that eliminates discharge. Mylan maintains all applicable permits and authorizations for wastewater discharge with governing authorities and complies with all local discharge limits.

Our facilities are equipped with air emission control devices as required to manage regulated air pollutants. Examples include high-efficiency dust collection, HEPA filtration, electrostatic precipitation, primary and secondary condensers, multi-stage filtration and recirculation systems, process scrubber technology and regenerative thermal oxidizers.

Please see Appendix for additional data.
Production requirements of our operations – coupled with local regulations and infrastructure – guide the type of water and wastewater management systems and processes we utilize. Due to these requirements, a significant amount of water is rejected as part of the purification processes and is discharged as wastewater. We are focusing efforts on how to improve this process and identify options to reuse this water.

We also continue to implement technologies to manage and reduce the amount of wastewater and effluents from our processes. We commissioned a new zero liquid discharge (ZLD) plant at one of our Bangalore, India, facilities bringing our number of ZLD sites to 10. We also made additional upgrades to effluent treatment plants at our other facilities in India. In 2018, we partnered with a garment maker in India to supply them with clean water from two ZLD plants for use in their facility and processes, helping to decrease the amount of water they require from the local municipality.

To ensure our ZLD-equipped plants continue to operate effectively, we conducted independent, third-party assessments in 2018 of two of our ZLD facilities in India.

Further, we use tools from various non-governmental organizations (NGOs), such as the World Resources Institute, to help perform water risk assessments. Withdrawal and discharge permits are maintained at all sites as required, and all operations sites are periodically audited to ensure compliance with local regulatory and internal standards.

**ZERO LIQUID DISCHARGE (ZLD) SYSTEMS**

1. Wastewater is collected and treated in various types of tanks. Microorganisms break down impurities. Solids and liquids are separated.

2. The resulting wastewater is filtered multiple times using reverse-osmosis technology. Up to 90% of the water treated can be recycled for non-potable uses, such as boilers or cooling towers.

3. The remaining liquid is subjected to evaporation technologies – the heart of ZLD processing. More non-potable water is harvested. Dried solids are collected for disposal.

ZLD systems are wastewater treatment plants that eliminate effluent discharge into the environment. Instead, all wastewater is treated and repurposed back into non-potable applications in our facilities, reducing water usage and significantly reducing environmental impact.
Waste Reduction

One of the many ways we strive to lessen our environmental impact is through appropriately managing and reducing hazardous and non-hazardous waste generated from our scientific practices, manufacturing processes, maintenance activities and administrative functions.

Mylan’s companywide EHS standards, along with industry regulations, govern specific handling, treatment, storage and disposal of all waste. Waste treatment methods are selected based on the type of waste and treatment requirements. We strive to use recycling, reuse and energy recovery options, including waste-to-energy facilities, cement kilns and fuel-blending facilities where possible to treat waste.

Throughout all our operations, we are committed to reducing waste through responsible use of resources, increased recycling, reuse of materials and initiatives dedicated to waste minimization. Across our sites, we recycled, reused or repurposed 26% of total waste generated and 44% of total waste generated was sent to various energy recovery facilities. More than 95% of our pharmaceutical waste is diverted from landfills to incineration or energy recovery facilities. We continue to strive to reduce or eliminate the amount of waste sent to landfills and are looking to increase our number of zero landfill sites. We encourage our patients and consumers to dispose of unused or expired products or waste materials in accordance with local regulatory requirements.

Improve Packaging Processes

At Mylan, we continuously evaluate ways to make all our processes more efficient while reducing materials. This includes our product packaging operations. In 2018, a team at our facility in Confienza, Italy, worked with a supplier to modify the design of the outer packaging of pump dispenser bottles for Saugella Girl and Babygella, a hygiene products line produced from natural plant extracts. The new design will reduce the use of plastic wrap per bottle by 88%. They also created a new, more efficient packaging process for these products that will begin in early 2019.

Mylan has also moved toward building a more sustainable future by undertaking cartonless packaging in its ARV business. Cartonless packs help eliminate traditional cardboard, allowing more bottles to be packed in each shipper while reducing the total volume of goods by an average of more than one-third. Cartonless packaging also adds value throughout the supply chain in the form of reduced freight volumes which help in optimizing valuable storage space in warehouses, distribution centers and health clinics. The Global Fund has estimated that switching to cartonless packaging reduces the cost of annual treatment by $1.80 per patient.

Please see Appendix for additional data.
As a pharmaceutical company and member of the global community, Mylan is committed to caring for the environment and promoting responsible manufacturing by taking steps to minimize the environmental impact of our operations and products, while also balancing our need to produce high quality, life-saving medication.

The primary pathways for pharmaceuticals entering the environment from human use are by normal patient excretion and improper disposal of medicine by consumers, in addition to the use of pharmaceuticals in agriculture. A significantly smaller contribution stems from emissions resulting from the pharmaceutical manufacturing process, which is attributed to less than 2% of the overall contribution.

While gaps remain in the scientific link between pharmaceuticals in the environment and human health risk, we are committed to reducing pharmaceuticals discharged from our manufacturing operations. Mylan’s approach to addressing and minimizing the potential impact of pharmaceuticals in the environment (PiE) from our own manufacturing is based on a wide range of activities and governance:

**RISK AND IMPACT EVALUATION**
Mylan conducts environmental risk evaluations of its products to assess a wide range of environmental risk factors. Mylan also assesses its manufacturing processes and wastewater treatment facilities to ensure that adequate systems and controls are maintained.

**RISK REDUCTION AND CONTROL**
Mylan minimizes discharges of active pharmaceutical ingredients from operations through enhancements in equipment, containment and cleaning processes. We continue to monitor potential emissions to the environment from our operations and implement appropriate controls if necessary.

**ENGAGEMENT AND POLICY**
Mylan supports and works to promote scientifically-based efforts to address PiE through initiatives of regulators, stakeholders and industry to close gaps and share best practices. We actively engage in industry associations and working groups to advance policy and effective solutions on PiE.

---

**Working Together to Fight Antimicrobial Resistance (AMR)**
Mylan is a proud member of the AMR Industry Alliance. In addition to board membership on the Alliance, Mylan is also a member of the organization’s manufacturing work group, partnering with industry leaders and companies on AMR strategies. We supported Alliance initiatives including the Common Antibiotic Manufacturing Framework in 2018. This represents the industry’s effort to provide a common methodology to assess potential risk from antibiotic discharges and take appropriate action when necessary.

---

2. BIO Intelligence Service (2013), Study on the environmental risks of medicinal products, final report prepared for Executive Agency for Health and Consumers, pp. 46-47
Climate Change and Energy

We are committed to responsible energy and greenhouse gas (GHG) emissions management through strategic energy sourcing and on-going improvement of our energy management systems. We continuously evaluate and identify opportunities to lower our energy demand usage and decrease GHG emissions.

We continue to work toward reducing our absolute total GHG emissions (Scope 1 and 2) as part of our work to support responsible manufacturing efforts, the U.N. Global Compact and SDG 13 for Climate Action.

Many of our sites completed energy management projects this past year such as making equipment improvements, installing LED lighting and purchasing renewable energy. Our manufacturing site in Merignac, France, was certified to ISO 50001, bringing our total to eight sites globally-certified to the ISO Energy Management standard. We continue to identify opportunities to phase out certain ozone-depleting substance (ODS) refrigerants and upgrade equipment at many facilities. In Dublin, Ireland, our Damastown oral solid dose facility replaced an older chiller with a unit that is more efficient and uses a refrigerant that is not an ozone-depleting substance. We also purchased 72 million kilowatt hours of renewable energy from local renewable energy suppliers, an increase of approximately 30% since 2017.

Looking forward, we are evaluating a longer-term science-based target for our Scope 1 and 2 GHG emissions.

Engagement with CDP

Mylan began participating in the CDP Climate Change disclosure program in 2017. In 2018, we also submitted our first CDP Water Security response, as well as became an official CDP Supporter. Nearly 7,000 disclosure responses are submitted to CDP globally. Mylan received a score of "B-" (management level designee) for both our Climate Change and Water Responses in 2018, improving our Climate Change score and achieving a Water Security score above the sector average. We are proud of our efforts to promote the importance of sustainable manufacturing. Our engagement with CDP reflects our commitment to the strategies and actions associated with good environmental management and our desire for continuous performance improvement.

Please see Appendix for additional data.
04
Better Global Public Health

CHAPTER SNAPSHOT

Key 2018 Accomplishments
- Continued to advocate for policies that break down barriers to access across the globe
- Facilitated improved understanding among regulators of the causes of drug shortages to define policies that will help enable supply

Current Challenges
- Structural issues in the U.S. healthcare system that hinder patient access to more affordable generics and biosimilars medicines
- Potential for inclusion of intellectual property (IP) provisions in trade agreements that would lengthen the time for generics and biosimilars to reach the market

Future Opportunities
- Continue to lead discussions on health reform and biosimilar policy with governments and health authorities around the world
- Take a leading role in ensuring policies focus on long-term health system strength and do not sacrifice patient access to medicine
Global Public Health

Good health is a precursor not only to individual well-being but also to the well-being of communities and nations around the world. It impacts socioeconomic status, productivity and the ability of each member of the world’s population to contribute to the greater good. Escalating healthcare costs, aging populations and the rising incidence of non-communicable diseases, coupled with lingering issues around infectious diseases, are among the global public health challenges we face today. Populations in low- and middle-income countries face added difficulty as access to preventive care, healthcare providers, diagnostic equipment and medicine is often limited or non-existent.

Sustainable access, regulatory requirements, IP barriers, and antimicrobial resistance (AMR) are among the key issues Mylan is addressing as we partner to help solve global health challenges. We understand that our industry plays a critical role in improving health and we relentlessly advocate for policies and progress that enable us to affect positive change.

Establishing Partnerships that Make a Difference

No single company, entity or government can address the issue of global public health on its own. Public and private partners representing the entire healthcare continuum must work together, pooling expertise and resources to determine a collaborative path forward that will best serve patients. We join forces with organizations whose public health goals complement ours, especially when it comes to raising awareness, increasing access and advancing industry sustainability. We’ve created strong, innovative alliances resulting in shared goals, trust and mutual respect to develop programs, legislation and partnerships that improve access to high quality medicine. We work with industry colleagues, governments and non-governmental organizations (NGOs) to affect change and enhance health through the provision of new and affordable medicine.

Some of our key global partners include UNAIDS; Global Fund to Fight AIDS, TB, and Malaria; PEPFAR (President’s Emergency Plan for AIDS Relief); the Clinton Health Access Initiative; the Bill and Melinda Gates Foundation and the WHO. We also work directly with regulatory bodies and trade associations to provide constructive input, raise awareness and propose solutions to challenges experienced by the generics and biosimilars medicines industry.

We actively participate and hold leadership roles (including president and vice president roles) in more than 55 industry associations and working groups across the globe.

Over the past year, our work with the Association for Accessible Medicines (AAM) in the U.S., Medicines for Europe and the International Generic and Biosimilar Medicines Association (IGBA) among other generic and biosimilar trade associations, gave us the opportunity to engage and educate stakeholders on the value of generic and biosimilar medicines. We also discussed policy issues ranging from sustainability of markets to antimicrobial resistance (AMR) with global health leadership, including the WHO. Additionally, Mylan experts worked with the WHO on the development of a drug shortage policy by providing insight on vulnerability in the global supply network and the economic underpinnings of drug shortages. We also advocated for more generic access language in two U.N. declarations on tuberculosis and non-communicable diseases.

Furthermore, we continued our involvement with the International Conference on Harmonisation (ICH). The ICH brings together regulatory authorities and the pharmaceutical industry to discuss and harmonize scientific and technical aspects of drug registration. We’ve worked closely with generic trade associations globally to promote a greater role for generics at the ICH and now have experts on six ICH expert working groups, more than any other generic drug company.
Overcoming Obstacles to Access

In 2018, we continued to work to receive approval on products that for many years were out of reach for patients around the world. Many of these products had no or very limited generic or biosimilar competition, therefore the high cost of these life-saving medications restricted access for patients. We have fought to expand access around the globe by developing less costly medicine in areas such as HIV/AIDS, women’s health, hepatitis, heart disease, diabetes, oncology and respiratory.

Our achievements in improving access to biosimilar medicines and generics through our approvals, regulatory submissions and R&D pipeline demonstrate how we continue to positively impact global public health, enabling patients to have an alternative to high-cost medications and improved access to these important medicines.

Advocating for Change in the U.S.

We continue to advocate for changes to the current structural issues in the U.S. healthcare system that hinder access to generics and biosimilars. To that end, we are encouraged by recent government proposals that strive to ensure that generic and brand products are placed on proper formulary tiers to lower out-of-pocket costs for patients, encourage use of generics and biosimilars, as well as create a much-needed generic and biosimilar tier for specialty products. We applaud these proposals and look forward to patients benefitting from the U.S. system the way that it was intended. This will encourage generics and biosimilars and allow innovation and competition to drive each other, which in turn creates further access to more affordable medicine.

SUPPORTING OUR GLOBAL HEALTH PARTNERS

U.S. Pharmacopeia (USP) is a globally recognized non-profit organization that develops quality standards to help safeguard the drug supply and promote access to quality medicines in more than 140 countries. These standards promote public health by giving regulators, the pharmaceutical industry and other stakeholders access to publicly-available specifications and methods to confirm the identity, potency, purity and performance of a medicine.

Mylan supports the important work of USP by donating scientific methods and expertise as well as drug product materials to develop new and revised quality standards. Mylan did so more than 50 times in 2018, earning a certificate of appreciation from USP’s CEO. By supporting the standards-setting process, Mylan helps to expedite the development of new and revised standards, which facilitates patient access to quality medicines and improves public health worldwide.
Addressing Trade Policy, Intellectual Property and Other Potential Barriers to Access

The pharmaceutical industry is truly global – patients on one continent may depend on a medicine that was made and packaged on multiple other continents. This interconnectivity requires inclusive, responsible policies and trade agreements that encourage competition and prioritize patient needs.

Advocating for Responsible Trade Policy and More Efficient Drug Approvals

While more work needs to be done, in 2018 we helped commission three surveys on the importance of a balanced trade agreement and the impact of trade on consumers in the U.S. and Canada. Mylan has publicly spoken on why trade agreements must strike a better balance between promoting innovation and ensuring expedited access to affordable drugs. In 2018, Mylan participated in a roundtable discussion in the U.S. Congress on the U.S.-Mexico-Canada (USMCA) Free Trade Agreement.

In 2018, we also demonstrated to regulators across different markets the significance of allowing generics and biosimilars to use a single comparator reference product when seeking drug approvals. This approach will support approval in multiple markets, saving money and time and will be more ethical, avoiding the need to expose additional human subjects for duplicative testing.

Protecting Intellectual Property while Prioritizing Patient Health

We work to reduce regulatory burdens that impede access to affordable medicine, such as slow approval processes and unnecessary hurdles. While we know companies must be profitable to demonstrate shareholder value, companies must also be careful not to undermine access through prolonged patent exclusivity and IP protection. Examples of excessive IP protections include patent term extensions or provisions related to data access, market access or approval processes that make bringing generics to market overly burdensome.

In 2018, we shared our concerns with authorities regarding the impact escalating IP protections can have on access. This work was done in conjunction with the International Trade Commission on the USMCA and other international bodies including the World Intellectual Property Organization, the World Trade Organization and several local stakeholders.

We encourage regulators to take practical, reasonable approaches to regulation to prevent global escalation of intellectual property protections that also may delay timely patient access to affordable medicine.
**Additional Global Public Health Efforts**

Experience tells us that companies can either stand in the way of access to affordable medicine or facilitate it. We choose the latter. By advocating on policy issues around the world, providing input to governments working to solve technical and regulatory hurdles, leading industry organizations and participating in global consultations, we are working to ensure medicines are accessible and more affordable. Here are some examples:

<table>
<thead>
<tr>
<th>ISSUE</th>
<th>2018 ACTIVITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Access to medicine</td>
<td>Continued advocating to enable Manufacture for Export (MFE), which will help strengthen the global supply of medicine. Also collaborated with the Australian government to improve the country’s IP framework to ensure timely access to generic and biosimilar medicines.</td>
</tr>
<tr>
<td></td>
<td>Worked with the Canadian Generic Pharmaceutical Association (CGPA) and Canadian officials to provide additional insight and discuss options regarding negative implications the USMCA may have on patients’ ability to access biosimilars at a reduced cost. We also participated in the CGPA/pan Canadian Pharmaceutical Alliance (pCPA) working group to develop a policy and complementary tiered-pricing framework to ensure generic drugs will continue to be accessible.</td>
</tr>
<tr>
<td></td>
<td>Worked with the Ministry of Health (MoH) in India to explore the possibility of including medicine to treat multi-drug-resistant tuberculosis (MDR-TB) and hepatitis in national health programs.</td>
</tr>
<tr>
<td></td>
<td>Successfully pioneered the launch of PrEP (Tenofovir/Emtricitabine) in Irish retail pharmacies and supported the world’s largest PrEP trial in the U.K. focusing on an estimated 10,000 people at high risk of HIV infection. Pre-exposure prophylaxis is a course of anti-HIV medications individuals take to reduce the risk of becoming infected if they are exposed to the virus. We also supported work to implement nationally-reimbursed PrEP programs in Ireland and Germany.</td>
</tr>
<tr>
<td></td>
<td>Contributed to a new law in Portugal. Highlights include: increased access to medicine, earlier access to generic medicine and the creation of savings for the national health system and patients.</td>
</tr>
<tr>
<td></td>
<td>The launch of Mylan’s Glatiramer Acetate (GA) ensured improved GA affordability. In the U.K., we encouraged the reintroduction of GA in the revised National Institute for Health and Care Excellence (NICE) guideline for MS treatment, facilitating ongoing NHS funding through specialized commissioning. Mylan was awarded framework tender status in England recognizing best value.</td>
</tr>
<tr>
<td></td>
<td>Helped commission three surveys on a balanced trade agreement and its impact to consumers in the U.S. and Canada. Also, participated in a roundtable discussion in the U.S. Congress on the U.S.-Mexico-Canada (USMCA) Free Trade Agreement.</td>
</tr>
</tbody>
</table>
### ISSUE

<table>
<thead>
<tr>
<th>Use/acceptance of generics and biosimilars</th>
<th>2018 ACTIVITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collaborated with the Generic and Biosimilar Medicines Association and advocated the Australian government to encourage the uptake of generics and biosimilars as a policy solution.</td>
<td></td>
</tr>
<tr>
<td>Collaborated with the CGPA to ensure Mylan branded products and biosimilars remain accessible and affordable for patients and worked with Biosimilars Canada to provide feedback to the pCPA, resulting in the publication of the ‘Biologics Policy Directions &amp; pCPA Negotiations’ guidance document, which is highly supportive of biosimilars introductions.</td>
<td></td>
</tr>
<tr>
<td>Helped develop a new biosimilar position paper in Italy, asserting safety in switching between originators and biosimilars.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Regulatory approval</th>
<th>2018 ACTIVITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Worked with the French government to shorten the time for receiving market authorization (MA), as part of a dedicated government initiative. Also created a project that allowed the reduction of the number of pending MAs from 72 to 13.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Self-tests</th>
<th>2018 ACTIVITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supported work done by the MoH to approve HIV self-tests to be sold at the pharmacy level in Germany.</td>
<td></td>
</tr>
</tbody>
</table>

### Preparing for Brexit

The formal change in the relationship between the European Union ("EU") and the U.K. as a result of the U.K. referendum to leave the EU ("Brexit") brings a level of patient impact along with significant uncertainties and implications for companies, governments and society at large. Supply and distribution of life-saving medicine could be negatively impacted. Mylan is continuing to actively work with national regulatory bodies, industry associations, members of the EU Parliament and the EU Commission to promote continued regulatory alignment, safeguard smooth product transfers and ensure that medicines can cross borders.
Antimicrobial resistance (AMR) continues to be a major global public health problem negatively impacting the lives of hundreds of thousands each year. For this reason, in 2016 the U.N. called for concerted action from governments and various business sectors to address the implications of AMR. Low-income and middle-income countries are disproportionately burdened. Contributing factors include patients’ vulnerability to invasive bacterial illness, irrational use of antibiotics and poor laboratory support for clinical diagnosis resulting in overuse of antibiotics.

Mitigating AMR requires a holistic approach and multi-stakeholder cooperation to address issues such as universal access to antimicrobials, appropriate use, surveillance, stewardship and responsible manufacturing. As a global healthcare company, we must consider the diverse needs and circumstances of patients and communities when supporting and developing measures to address AMR. Policy intended to protect patients in one region may create unintended disadvantages for patients in another.

Mylan is a signatory to the Davos Declaration on combating AMR and a founding board member of the AMR Industry Alliance. The Alliance is one of the largest private sector coalitions established to provide sustainable solutions to curb AMR. It has rallied more than 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations to join forces against this issue. The Alliance measures and drives the progress of the life-sciences industry to curb AMR in four areas: appropriate use; access; research and science; and the environment. Mylan adopted the AMR Industry Alliance Common Antibiotic Manufacturing Framework in 2018 and is an active member of its manufacturing work group. We also participated in the Access to Medicine Foundation’s Antimicrobial Resistance Benchmark 2018.

In addition to the AMR Industry Alliance, we engage on AMR issues through our national and regional trade associations, NGO collaborations and the Eco-Pharmaco-Stewardship Inter-Association Initiative, a cross-industry collaboration on environmental issues. In India, we are also engaged with the Ministry of Environment, Forest and Climate Change (MOEF) and other agencies regarding AMR.

Educating to Combat AMR
Mylan partnered with medical schools in India to educate residents on the rational use of antimicrobial agents in managing infections. Training on this topic is especially important in India where a high disease burden, poor public health infrastructure, rising incomes and unregulated sales of antibiotics have amplified the crisis of antimicrobial resistance.
Key 2018 Accomplishments
- Donated hundreds of millions of doses of medicine to assist patients in need
- Created a new global structure to more effectively coordinate our philanthropic initiatives across regions and functions

Current Challenges
- Scaling the coordination of our growing philanthropic efforts worldwide

Future Opportunities
- Continue to build an effective and efficient global philanthropic framework, tools and strategic focus
Supporting Communities

In addition to our focus on providing high quality medicines to people who need them, we know many other factors affect someone’s ability to live a healthy life. That’s why we continually work to identify additional ways to positively impact our community.

Whether through monetary contributions, product and service donations, program and event support or through our employees contributing their time and expertise to help others, our efforts are aimed at improving quality of life by responding to local needs and circumstances.

We currently manage community initiatives based on region. For example, in India, we have a very robust program honoring the India Companies Act, which mandates that companies spend 2% of their average net profits (made during the three immediately preceding financial years) on corporate social responsibility initiatives. In the U.S., Mylan has a donations policy and committee that manages contributions. Mylan country managers oversee community initiatives in other regions in accordance with local and company policies. The Mylan Charitable Foundation, an independent 501(c)(3) organization, also provides financial support to help meet community education, social services and health needs, among other areas.

**Enhancing Our Commitment to Global Philanthropy for the Future**

As our organization has grown, we have continued to expand our reach and impact. To ensure we are making the most of our collective efforts, we are in the process of creating a new global infrastructure to more effectively coordinate these initiatives across regions and functions.

To advance this work, we have begun a priority initiative to build the framework, tools and strategic focus required to form more cohesive philanthropic planning, decision-making and tracking mechanisms across our organization. The establishment of this globally coordinated philanthropic effort will be overseen by our Head of Global Sustainability.

Since Mylan was founded, “giving back” has been a core value and common practice as we strive to strengthen the communities where we live and work.
In 2018, our community engagement efforts were as diverse as the regions we serve and the people they helped.

The following pages highlight just a few of the ways we supported local education, health, social initiatives and other community efforts.
Empowering West Virginia Children to be Curious, Active, Resilient and Engaged (CARE) through STEM

In a new collaboration with West Virginia University (U.S.), Mylan committed a $5 million charitable contribution over 10 years to develop and implement a program that will expose children across the state of West Virginia to STEM (Science, Technology, Engineering and Math) and challenge traditional thinking about how STEM skills can be applied. Called STEM-CARE, it is intended to inspire West Virginia’s youth by demystifying STEM and showing children that STEM curricula and career opportunities are valuable for those who want to pursue paths beyond being engineers or lab scientists. It aims to expand a student’s vision of career possibilities and potential education tracks, whether it be a technical degree or program or an alternate form of higher education. The program’s basic tenets will reinforce that STEM skills are fundamental for solving everyday challenges, from managing personal finance to following a recipe in the kitchen, and other important life skills.

Improving Sanitation and Access to Clean Water in India

Improving access to clean water and sanitation is a focus for Mylan India. Of the 1.7 million people who die from unsafe water, sanitation and hygiene each year, more than 600,000 are in India.¹ And according to the U.N., 30 million children there do not have access to toilet facilities in schools.² While approximately 80% of India’s primary schools are operated by the government,³ nearly half of these schools don’t have usable toilet facilities for female students causing an alarming drop-out rate of 23%⁴ for adolescent girls.

To help address these issues, Mylan India is implementing a comprehensive sanitation and hygiene program in schools across the states of Tamil Nadu, Karnataka, Telangana, Andhra Pradesh and Madhya Pradesh.

Over the last three years, Mylan India has provided 21 toilet facilities to schools in different states under the Swachh Vidyalaya program,⁵ with eight multi-unit facilities installed in 2018 benefiting around 2,600 students.

Mylan also provided five schools in Parwada Mandal, Visakhapatnam with reverse osmosis (RO) purification water systems. This initiative will benefit approximately 1,500 children by providing them with clean, safe drinking water. Additionally, in an effort to assist communities with proper collection of solid waste, Mylan donated garbage disposal trucks to four villages.

¹https://www.gatesnotes.com/Development/Indias-War-on-Human-Waste
²http://in.one.un.org/page/sustainable-development-goals/
⁵The Ministry of Human Resource Development has launched Swachh Vidyalaya Programme under Swachh Bharat Mission with an objective to provide separate toilets for boys and girls in all government schools.
For more than 30 years, Mylan has manufactured medicines in Puerto Rico, and we are committed to helping the territory and its citizens after Hurricane Maria devastated the island. In 2018, the Mylan Charitable Foundation approved a $1 million grant to SBP, a nonprofit helping with the long-term recovery efforts and rebuilding of homes. To date, SBP has repaired 40 homes, and with the Mylan Charitable Foundation’s support as a leading partner, they are on track to rebuild 100 homes throughout 2019.

Donated hundreds of millions of doses of medicines to organizations such as Americares, Brother’s Brother, Direct Relief International, Dispensary of Hope, Health Partners International of Canada and Heart to Heart International, among others, to assist those in need.

Supplied boxes of allergen chambers to the Bulgarian Dermatological Society for a skin allergy initiative aimed at helping those who suffer from chronic allergic diseases.

Responded to severe drought in Australia by donating funds to supply farmers with much needed hay for livestock.

Sponsored the Bang Len Football Academy youth football program in Thailand for the seventh year in a row. The program helps kids develop life skills and encourages a healthy lifestyle.

Promoted AIDS awareness and prevention targeting youth and vulnerable populations around the world. Work included publications, campaigns, screenings and community outreach.
Participated in marathons supporting cancer and cardiovascular disease patients, children with disabilities and women’s empowerment, among others. Hundreds of employees in Bulgaria, France, Germany, Ireland, Romania, Spain, Turkey and the U.S. joined races across the globe.

Contributed products for medical missions supported by AusViet Charity, Cambodia Vision, Philippine Australian Medical Association, Rotary Australia World Community Services and Youth with a Mission (Papua New Guinea).

Supported a variety of children’s causes in Finland, Greece, Hungary and the U.S. with donations such as food, first aid supplies, and holiday gifts.

Donated funds to help rebuild the lives and homes of those affected by flooding in Kerala, India.
Key 2018 Accomplishments
- Increased our engagement and dialogue with stakeholders
- Added GSR to the charter of the Risk Oversight Committee of Mylan’s Board of Directors

Current Challenges
- Continuing to safeguard the integrity and continuity of our business as we encounter evolving regulations and requirements and advance into new geographies

Future Opportunities
- Utilizing our new Business Transformation office to bring additional discipline to our next phase of organic growth
- Continuously improving the sustainability of our operations and those of our suppliers
We continue to recognize the growing interest in GSR management, performance and transparency as the investment community and others integrate environmental and social factors, in addition to existing governance factors (ESG), into their priorities. Capital is increasingly directed towards companies that seek to realize opportunities and create value by solving societal challenges while effectively managing inherent risks. Our business model – built on access, diversification and durability – enables us to do just that.

A Strong Foundation
Mylan has created a durable business model which includes significant diversification in our commercial, operational and scientific platforms with no reliance on one single product or geographic area. While the U.S. market remains important, we are steadily growing our business and revenues in Europe and the Rest of World. Our product portfolio, manufacturing capabilities and global operating platform enable us to support the needs of patients and customers around the globe.

Building for the Future
As we look to Mylan’s future, sustainability cannot be dependent on prior success alone. Although Mylan’s next phase of evolution will predominantly be driven by organic growth, it will require a company willing to reinvent itself in order to further build upon its success while keeping pace with ever-changing market dynamics. We are driving capital market disciplines into every segment of our business, distinguishing between value-creating and value-consuming assets. We’ve formalized that work and have established a Business Transformation office that is using a highly disciplined financial lens to unlock latent value from the assets we’ve integrated throughout the company.

Through this rigorous process, we seek to deliver continued long-term growth and attractive shareholder returns by maximizing new products, reallocating investments to drive share of economically profitable products, all while maintaining a competitive sourcing and manufacturing footprint.

Stakeholder Outreach
We increased our engagement and dialogue with our stakeholders in 2018. Topics of interest included pricing, quality and risk management, company culture and environmental impact. Our approach to supporting the SDGs was also a recurrent theme.

We welcomed the opportunity to share what we believe differentiates Mylan and demonstrate why we are a relevant partner dedicated to doing what’s right, not what’s easy. These conversations also informed our GSR issues assessment and related GSR oversight enhancements.

Net Sales by Segment
- North America: 36%
- Europe: 37%
- Rest of World: 27%

Net Sales by Product Type
- Rx/Bx
- Gx
- OTC

Total Revenues: $11.4B
Global Social Responsibility Governance

We are further integrating relevant GSR components into our strategic and operational efforts. To support top-level commitment and visibility to GSR, Mylan’s Head of Global Sustainability now reports to Mylan’s CEO. This function oversees the development and execution of Mylan’s goals on relevant GSR topics and philanthropy. Additionally, a multifunctional GSR Advisory Committee comprised of senior leaders convenes monthly and supports the integration of relevant GSR topics across the organization. To ensure top-level accountability, Mylan’s Risk Oversight Committee, established by Mylan’s Board of Directors in 2018, oversees management’s efforts with respect to GSR.

Risk Governance

We operate in a complex and rapidly changing environment and must uphold adequate oversight and processes to manage enterprise risks and support the continued growth of our company. The previously mentioned Risk Oversight Committee was formed by our Board of Directors to support its supervision of the company’s enterprise risk management framework. Together with the Board’s Audit and Compliance Committees, the Risk Oversight Committee ensures oversight of management’s responsibilities to identify, assess and manage material risks, and the chairs of these committees will meet at least semi-annually to discuss risk-related matters to ensure there is cohesive oversight by the committees on behalf of the Board.

To operationalize our Enterprise Risk Management (ERM) program, Mylan established a Risk Management Team (RMT) in 2018 to identify risks and opportunities and to evolve organizational readiness. It reports to Mylan’s Executive Governance Team and includes many of Mylan’s most senior leaders as well as Mylan’s Head of Global Sustainability and Head of Global Internal Audit.

Risk Management

Mylan is committed to operating ethically and with integrity and seeks to apply a holistic approach to risk management. By embedding the company’s strategic planning process into our ERM processes, we identify and manage risks while also identifying and managing opportunities.

In 2018, we enhanced our enterprise risk assessment, a significant component of the company’s ERM program used to identify and mitigate emerging and key risks. As we conducted our first comprehensive GSR priority assessment, we took the opportunity to align the processes, allowing for the GSR priority assessment to inform the enterprise risk assessment and ultimately the company’s risk profile.¹

As we expand into new geographies – potentially with increased risk profiles – safeguarding integrity in business conduct is critical. Mylan has well-established procedures to identify, mitigate and monitor risks as part of expanding our business. More specifically, risks associated with expansion into new geographies is an element of our ERM program which is leveraged by Internal Audit in determining areas over which it will perform audits.

¹For more detailed information about the risks and uncertainties associated with our business activities, see our Annual Report on Form 10-K for the year ended Dec. 31, 2018.
Ethical Marketing and Promotion

Mylan employees often interact with members of the healthcare community as part of their efforts to educate on the appropriate use and efficacy of Mylan's products. These interactions are important and fundamental to increasing patient access but may bring elevated risk. We have well-established global, regional and local policies and procedures that inform employees on appropriate interactions with the healthcare community and requirements pertaining to drug promotion and ethical marketing. Risk assessments and employee training are key components of each. We strive to comply with regulations and adhere to ethical standards set forth by Mylan and industry associations.

Mylan's Global Policy for the Marketing and Advertising Review Council requires the establishment of local procedures to ensure that all promotional materials and other commercial communications are reviewed and approved internally by appropriate subject matter experts. The goal of the local review procedures implemented under the policy is to ensure that all materials and communications intended for promotional or commercial purposes are accurate, truthful, medically/scientifically sound, not misleading and compliant with all applicable marketing, legal, regulatory and medical requirements and company policies.

Mylan's Balanced Pricing Model

Given our long history of providing high quality, low-cost generic pharmaceuticals, we are uniquely situated to work with customers, payors, non-governmental organizations (NGOs) and other partners to find solutions and meet the needs of the patients and families we serve. We also have a strong track record of developing new products, particularly complex and difficult-to-formulate medicines, and are committed to making safe, high-quality products accessible to patients across all income levels.

With respect to Mylan's generic portfolio, we offer hundreds of affordable products all at a fraction of the price of the equivalent brand name medicine. The prices of these drugs often decrease every year. As negotiations occur with our customers or as we participate in tender programs or public/private partnerships around the globe, we will continue to do so based on an assessment of supply, demand, patient need and the affordability of our product, especially as it relates to the equivalent brand name drug.

As it pertains to our brand portfolio, Mylan is committed to pricing its products in a way that reflects their value to patients and providers. Mylan will endeavor to not raise the prices of our branded products more than once per year, however, we will assess the prices of our products on a regular basis. Our aim is for any price increases to be reasonable in light of relevant factors, including current economic indicators and the state of the overall business marketplace.

The socioeconomic conditions within each market that Mylan does business are inherently considered as part of our generic and brand pricing assessments, as is the importance of sustaining our ability to consistently provide patients in each market with the quality products needed. This is reflected in our ability to provide 59 billion doses of medicine in 2018 to more than 165 countries and territories around the world at an average price of 19 cents per dose.

In connection with its oversight responsibilities, the Compliance Committee of Mylan’s Board of Directors reviews global compliance-related policies relating to pricing and/or commercialization of the Company’s products and services.
Upholding a Culture of Compliance and Good Conduct

Everyone at Mylan – and those acting on our behalf – is personally responsible and accountable for the company’s reputation and dedication to doing business with integrity. Mylan works to provide the adequate procedures and guidance to support that individual responsibility. Mylan’s Chief Administrative and Compliance Officer has the operational responsibility to ensure Mylan’s Corporate Compliance Program is effective and robust and directs its day-to-day implementation. To ensure broad perspectives and independence in the Compliance Office, Mylan’s Chief Administrative and Compliance Officer reports to the Board’s Compliance Committee and the Chief Executive Officer.

Key accomplishments in 2018 include:

- engaged an external consulting firm to conduct a compliance program effectiveness review, including relevant policy documents, processes, training materials and due diligence efforts;
- continued enhancement of Mylan’s employee data protection and privacy policies, processes and training to ensure compliance with the evolving Global Data Protection Regulation (GDPR) and other regulatory requirements; and
- successfully completed all year-one requirements under Mylan Inc. and Mylan Specialty L.P.’s Corporate Integrity Agreement with the Office of Inspector General of the U.S. Department of Health and Human Services (OIG) and submitted our annual report to the OIG.

Compliance Training

Mylan’s Code of Business Conduct and Ethics outlines guiding principles on how employees and those working on our behalf should conduct themselves. It also informs on policies and standards while providing high-level guidance on critical areas of the company’s business operations.

We require and provide dedicated training on anti-corruption, fair competition and Mylan’s Standards for Interactions with Healthcare Providers (for employees with relevant job responsibilities). Vendors that may interact with government officials on our behalf also receive anti-corruption training. Depending on their role, part-time employees and contractors are required to take subsets of the trainings listed above.

**OUR TRAINING GOALS**

**GOAL:** Maintain and communicate Mylan’s Code of Business Conduct and Ethics and train at least 90% of employees on the Code of Business Conduct and Ethics

- **96% TRAINED IN 2018**

**GOAL:** Maintain and communicate Mylan’s Anti-Corruption Policy and train at least 90% of Mylan’s applicable employees on the company’s Anti-Corruption Policy and related laws

- **100% TRAINED IN 2018**

**GOAL:** Maintain and communicate Mylan’s Fair Competition Policy and train at least 90% of Mylan’s applicable employees on the company’s Fair Competition Policy

- **96% TRAINED IN 2018**

*Denotes percentage of employees who are not overdue on each training as of Dec. 31, 2018.*
Training topics include but are not limited to:

- Code of Business Conduct and Ethics
- Anti-Corruption
- Fair Competition, Anti-Trust and Pricing Requirements
- Supplier Code of Conduct
- Standards for Interactions with Healthcare Providers
- Fair Employment Practices and Recognizing and Preventing Harassment, Discrimination and Retaliation
- Mylan’s Corporate Integrity Agreement
- C-TPAT (Customs – Trade Partnership Against Terrorism)
- General Privacy Overview
- Engaging Healthcare Professionals as Consultants, Advisory Board Members and External Speakers
- Records & Information Management and Good Documentation Practices
- General Data Protection Regulation (GDPR)

**Fighting Corruption and Promoting Fair Competition**


Our Global Anti-Corruption Policy strictly forbids bribery and corruption in any form anywhere we do business. The policy defines bribery and corruption, including facilitation payments, which are strictly prohibited even where permitted under law. Mylan has monitoring and auditing procedures in place to identify and deter such payments. We reassess our anti-corruption program periodically and make updates as warranted.

Through our ERM program, Internal Audit assesses anti-corruption and anti-fraud management over entities throughout the world from a corruption risk perspective. Size (the number of people and sales volume) and a country’s ranking in the Transparency International Corruption Perception Index (CPI) are key to informing the risk profile of an entity. Entities identified as higher risk along with those of strategic importance to Mylan are a particular focus. Further, we monitor business activities that are deemed an elevated risk – such as HCP interactions – through established internal processes and controls. Our procedures also address our business partners.

**Reporting Compliance Concerns**

Mylan encourages open communication, provides a variety of channels for reporting potential compliance violations and strictly prohibits retaliation of any reports made in good faith. Employees are encouraged to discuss compliance matters with their supervisor, Human Relations, the Legal department, their local compliance officer or the Office of Global Compliance. They also can use Mylan’s Compliance Line, which is operated by an external party. It is available 24/7 and permits anonymous reports in all countries in local languages where permitted by law. For investigating, resolving and remediating reported events, our Global Policy on Reporting and Investigating Compliance-Related Matters outlines a clear process that includes:

- review of every report by our Head of Global Compliance;
- a thorough, impartial and timely investigation of each report in coordination with Human Relations, our Legal department and other functions, as appropriate; and
- fair and consistent disciplinary measures, when necessary.

The policy is available to all employees on the company’s intranet.

Visit Mylan.com/GSR for more information.
Ensuring Good Conduct in Partnerships

External partners sometimes act as intermediaries on our behalf or in settings where special skills or expertise are required. Given their role, it’s essential these partners comply with Mylan’s ethical and anti-corruption standards and act with good judgment.

Mylan’s Office of Global Compliance (OGC) identifies business partner categories that may carry higher inherent corruption and/or reputational risk. These partners, noted during the business contract drafting and approval process, are subject to a risk review depending on the aggregated risk factors assigned, as well as other Mylan compliance standards. Those identified as having an elevated risk are subject to a due diligence process including investigation and clarification of discovered legal, civil and reputational allegations or convictions. If any concerns are discovered that cannot be adequately resolved, it’s our policy that the OGC recommends terminating the proposed business partnership.

Anti-corruption language, right-to-audit clauses and ethical expectations are included in Mylan contracts. Any potentially high-risk business partners undergo a due diligence review and annual monitoring.

GOAL

Train at least 90% of business partners who interact with government officials on Mylan’s behalf on our Anti-Corruption Policy and procedures.

Percentage trained in 2018: 96%
Enhancing Supplier Relationships

Mylan relies on its suppliers to deliver high quality, affordable and accessible products to our customers and ultimately to patients. Maintaining good relationships helps ensure a high quality and reliable supply. In 2018, we continued to build out our Supplier Relationship Management program, focusing on preferred suppliers, to enhance long-term strategic partnerships. Looking forward, we plan to continue to enhance our list of preferred suppliers by segmenting and consolidating our supply base, further reducing risk.

Mitigating Supply Chain Risk

We have a robust due diligence process to better understand supplier capabilities and ensure their ability to comply with regulatory and compliance requirements. Our source selection process is governed by a Source Review Committee (SRC), comprised of a cross-functional internal team from science, legal and sourcing. This team also manages the selection of API suppliers.

Mylan has a proactive risk mitigation program to protect the supply chain by strengthening supply agreements with current suppliers and qualifying alternate suppliers. We monitor performance through reporting, trend analysis and consistent business review meetings. Mylan has established escalation and cross-functional issue management processes. Sourcing teams routinely meet with suppliers to review the performance of supply and create action plans to address identified risks.

For our third party finished dose formulation suppliers, we maintain an end-to-end product management approach.
MANAGING SUPPLIER DIVERSITY IN THE U.S.

In 2018, Mylan worked to enhance awareness of its U.S. supplier diversity program among sourcing and procurement teams across the business. Senior management met quarterly to review goals and achievements and when necessary, recommend corrective action.

We have worked to build out relationships with small and diverse businesses. Mylan uses a supplier portal where suppliers are invited to register as an existing or potential supplier and provide their diversity status, certification and capabilities. This data is used during our competitive bidding process.

Thanks to focused efforts in 2018, Mylan achieved its overall diversity spend business goal for 2018, with a few target areas exceeding expectations.

Looking ahead, Mylan will continue to strengthen its small and diverse business engagement process by enhancing our training, reporting and enforcement programs. Internally, we expect to further highlight diverse suppliers and provide easy access to external databases for sourcing team members to utilize in the competitive bidding process. We also plan to implement an Indirect Sourcing Policy and track diversity sourcing adherence in the competitive bidding process where applicable.

Expanding Sustainable Sourcing

We plan to build out competency in sustainable sourcing processes and procedures across the organization. Mylan’s internal Council for Sustainable Sourcing oversees our practices and provides guidance on sustainable sourcing; sets annual goals and objectives; and develops, implements and monitors compliance with sustainable sourcing practices and metrics. All applicable employees must take bi-annual Supplier Code of Conduct training.

We continually work to improve our operations and expect our business partners to promote similar principles throughout their supply chain. Mylan expects our suppliers to act in accordance with applicable laws, regulations and our Supplier Code of Conduct which provides guidance for doing business with Mylan. The Supplier Code and our terms and conditions are available on Mylan.com and are referenced in our purchase orders. In 2018, our Supplier Code of Conduct was distributed to 100% of direct material suppliers and 58% of indirect suppliers. Our intent is to increase the distribution to our indirect suppliers as we move through 2019.

In 2018, Mylan revised its Supplier Code of Conduct, which can be found on our website, to more clearly align with the U.N. Global Compact and international conventions and to communicate our expectation that suppliers apply comparable standards throughout their supply chain.
Respecting Human Rights

As a signatory to the U.N. Global Compact, we understand our responsibility and opportunity to support and promote the protection of human rights beyond our own operations. We do so through our core business, how we conduct ourselves and in our dealings with partners. Mylan is committed to the 10 principles of the U.N. Global Compact and respects the International Bill of Human Rights and the Fundamental Conventions of the International Labour Organization.

Mylan’s global policies and associated procedures, employee and partner training and due diligence are the foundation of our work to mitigate the risk of human rights violations.

Topics critical to addressing human rights are addressed through a variety of Mylan policies including our Code of Business Conduct and Ethics, Supplier Code of Conduct, Global Policy on Combatting Human Trafficking in Persons and our companywide EHS program. Examples include:

- freedom of association,
- legal compliance,
- prohibition of trafficking of persons,
- prohibition of forced and child labor,
- handling of identity and immigration documents,
- wages,
- working hours,
- safety in the workplace,
- preventing harassment and
- recruitment practices.
## BETTER PATIENT HEALTH

### Our Access Key Performance Indicators

<table>
<thead>
<tr>
<th></th>
<th>As reported in 2017 GSR Report*</th>
<th>Data per 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doses sold</td>
<td>~69 billion</td>
<td>~59 billion</td>
</tr>
<tr>
<td>Number of products</td>
<td>&gt;7,500</td>
<td>&gt;7,500</td>
</tr>
<tr>
<td>Number of countries and territories reached</td>
<td>&gt;165</td>
<td>&gt;165</td>
</tr>
<tr>
<td>Therapeutic categories</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Coverage percentage of the top 10 causes of death globally</td>
<td>N/A</td>
<td>90%</td>
</tr>
<tr>
<td>Coverage percentage of the top 10 causes of death across low- and lower-middle income countries</td>
<td>N/A</td>
<td>77%</td>
</tr>
<tr>
<td>Products in development by region¹</td>
<td>North America: 359</td>
<td>North America: 340</td>
</tr>
<tr>
<td></td>
<td>Europe: 174</td>
<td>Europe: 200</td>
</tr>
<tr>
<td></td>
<td>Japan, Australia and New Zealand: 181</td>
<td>Japan, Australia and New Zealand: 41</td>
</tr>
<tr>
<td></td>
<td>Emerging Markets: 310</td>
<td>Emerging Markets: 947</td>
</tr>
<tr>
<td>Products pending approval by region¹</td>
<td>North America: 267</td>
<td>North America: 200</td>
</tr>
<tr>
<td></td>
<td>Europe: 528</td>
<td>Europe: 700</td>
</tr>
<tr>
<td></td>
<td>Japan, Australia and New Zealand: 41</td>
<td>Rest of World: 1,600</td>
</tr>
<tr>
<td></td>
<td>Emerging Markets: 947</td>
<td>Emerging Markets: 310</td>
</tr>
<tr>
<td>Types of products</td>
<td></td>
<td>See page 80</td>
</tr>
<tr>
<td>Average selling price of Mylan’s medicines</td>
<td>17 cents per dose</td>
<td>19 cents per dose</td>
</tr>
</tbody>
</table>

¹Products taken from internal data and rounded
## Our Access Key Performance Indicators

<table>
<thead>
<tr>
<th></th>
<th>As reported in 2017 GSR Report</th>
<th>Data per 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Customer service levels globally and by region</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>North America: 82.3%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rest of World: 95.7%</td>
</tr>
<tr>
<td>Percentage of low- and lower-middle income countries reached</td>
<td>N/A</td>
<td>90%</td>
</tr>
<tr>
<td>Doses sold in low- and lower-middle income countries</td>
<td>N/A</td>
<td>&gt;5 billion</td>
</tr>
<tr>
<td>Number of products on the WHO's Essential Medicines List</td>
<td>N/A</td>
<td>&gt;150</td>
</tr>
<tr>
<td>Number of products on the WHO list of prequalified products (including cross-listed approvals)</td>
<td>63</td>
<td>HIV/AIDS: 46</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Reproductive Health: 9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tuberculosis: 8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Influenza: 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Malaria 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hepatitis:1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total: 68¹</td>
</tr>
<tr>
<td>Active partnerships or organizational memberships related to increasing access to medicines</td>
<td></td>
<td>See pages 78-79</td>
</tr>
</tbody>
</table>

¹Including two approvals in January 2019
<table>
<thead>
<tr>
<th>Additional Access Data</th>
<th>As reported in 2017 GSR Report</th>
<th>Data per 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total investments in R&amp;D</td>
<td>From 2013-2017, we invested more than $3 billion in cumulative R&amp;D spend</td>
<td>$704.5M in 2018</td>
</tr>
<tr>
<td>Number of patents filed to date</td>
<td>~4,000</td>
<td>&gt;4,500</td>
</tr>
<tr>
<td>Number of clinical trials</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
<tr>
<td>Licenses via the Medicines Patent Pool</td>
<td>N/A</td>
<td>5</td>
</tr>
<tr>
<td>Percentage of the 69 FP2020 countries in which Mylan has registered its contraceptive portfolio</td>
<td>72% (50 out of 69 countries)</td>
<td>80% (55 out of 69 countries)</td>
</tr>
<tr>
<td>Number of women and girls in the FP2020 countries that Mylan provided contraceptives to</td>
<td>~11 million</td>
<td>~10 million</td>
</tr>
</tbody>
</table>

1Including FP2020 countries where Mylan’s portfolio is registered and FP2020 countries that Mylan supplies through the UN Population Fund (UNFPA)
## BETTER EMPLOYEE HEALTH

### Our People

<table>
<thead>
<tr>
<th></th>
<th>As reported in 2017 GSR Report</th>
<th>Data per 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mylan’s workforce</td>
<td>Total workers: 35,560</td>
<td>Total workers: 35,260</td>
</tr>
<tr>
<td></td>
<td>Employee: 31,828</td>
<td>Employee: 31,207</td>
</tr>
<tr>
<td></td>
<td>Temporary worker: 3,732</td>
<td>Temporary worker: 4,053</td>
</tr>
<tr>
<td>Workforce by region</td>
<td>North America: 21.2%</td>
<td>North America: 19.0%</td>
</tr>
<tr>
<td></td>
<td>Europe: 27.4%</td>
<td>Europe: 28.8%</td>
</tr>
<tr>
<td></td>
<td>Rest of World: 51.4%</td>
<td>Rest of World: 52.2%</td>
</tr>
<tr>
<td>Workforce by function</td>
<td>Operations: 58.0%</td>
<td>Operations: 57.1%</td>
</tr>
<tr>
<td></td>
<td>Sales &amp; Marketing: 19.7%</td>
<td>Sales &amp; Marketing: 21.0%</td>
</tr>
<tr>
<td></td>
<td>General &amp; Admin: 13.7%</td>
<td>General &amp; Admin: 13.7%</td>
</tr>
<tr>
<td></td>
<td>Scientific Affairs: 8.6%</td>
<td>Scientific Affairs: 8.2%</td>
</tr>
<tr>
<td>Employees by age group</td>
<td>Under 25: 4.2%</td>
<td>Under 25: 4.0%</td>
</tr>
<tr>
<td></td>
<td>25-34: 37.4%</td>
<td>25-34: 36.9%</td>
</tr>
<tr>
<td></td>
<td>35-44: 30.4%</td>
<td>35-44: 30.8%</td>
</tr>
<tr>
<td></td>
<td>45-54: 19.1%</td>
<td>45-54: 19.3%</td>
</tr>
<tr>
<td></td>
<td>55-64: 8.6%</td>
<td>55-64: 8.6%</td>
</tr>
<tr>
<td></td>
<td>65 and over: 0.3%</td>
<td>65 and over: 0.4%</td>
</tr>
<tr>
<td></td>
<td>Average: 39.4 years of age</td>
<td></td>
</tr>
<tr>
<td>Employee gender by region¹</td>
<td>North America: Female: 38.2%, Male: 61.8%</td>
<td>North America: Female: 40.7%, Male: 59.3%</td>
</tr>
<tr>
<td></td>
<td>Europe: Female: 55.3%, Male: 44.7%</td>
<td>Europe: Female: 54.9%, Male 45.1%</td>
</tr>
<tr>
<td></td>
<td>Rest of World: Female: 11.9%, Male: 88.1%</td>
<td>Rest of World: Female: 13.8%, Male: 86.2%</td>
</tr>
<tr>
<td></td>
<td>Globally: Female: 28.3%, Male: 71.7%</td>
<td>Globally: Female: 29.8%, Male: 70.2%</td>
</tr>
</tbody>
</table>

¹Based on Mylan’s HR information system

All references to “workers” and “workforce” include employees and temporary workers.
<table>
<thead>
<tr>
<th>Our People</th>
<th>As reported in 2017 GSR Report</th>
<th>Data per 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full-time equivalent workforce by region</td>
<td>N/A</td>
<td>North America: 97.9%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Europe: 93.2%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rest of World: 99.7%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Globally: N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Globally: 97.4%</td>
</tr>
<tr>
<td>Board diversity1</td>
<td>Female: 36.0%, Male: 64.0%</td>
<td>Female: 33.3%, Male: 66.7%</td>
</tr>
<tr>
<td>People managers by gender2</td>
<td>Female: 26.0%, Male: 74.0%</td>
<td>Female: 26.8%, Male: 73.2%</td>
</tr>
<tr>
<td>% of male employees responsible for managing</td>
<td>16.0%</td>
<td>15.8%</td>
</tr>
<tr>
<td>people as a percentage of total male population2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% of female employees responsible for managing</td>
<td>14.0%</td>
<td>13.1%</td>
</tr>
<tr>
<td>people as a percentage of total female population2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% of senior management that is female2,3</td>
<td>N/A</td>
<td>19.1%</td>
</tr>
<tr>
<td>Employee training and education</td>
<td>~2.5M learning activities</td>
<td>~2.9M learning activities</td>
</tr>
<tr>
<td>% of employees included in Mylan’s performance</td>
<td>N/A</td>
<td>96.6%</td>
</tr>
<tr>
<td>process4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Average employee tenure by gender2</td>
<td>N/A</td>
<td>Female: 8.4 years, Male: 7.5 years</td>
</tr>
</tbody>
</table>

All references to “workers” and “workforce” include employees and temporary workers.

1Includes CEO Heather Bresch
2Based on Mylan’s HR information system
3Grade 65+
4Not including employees covered by collective bargaining agreements in the U.S., employees on a leave of absence and new employees
### Our People

<table>
<thead>
<tr>
<th></th>
<th>As reported in 2017 GSR Report</th>
<th>Data per 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Employee turnover rate</td>
<td>Overall: 17.8%</td>
<td>Overall: 16.7%</td>
</tr>
<tr>
<td>Voluntary¹</td>
<td>N/A</td>
<td>Female: 8.9%, Male: 8.3%</td>
</tr>
<tr>
<td>Involuntary¹</td>
<td>N/A</td>
<td>Female: 4.5%, Male: 5.9%</td>
</tr>
<tr>
<td>Other¹²</td>
<td>N/A</td>
<td>Female: 1.7%, Male: 2.3%</td>
</tr>
<tr>
<td>New hire rate</td>
<td>N/A</td>
<td>Overall: 15.3%</td>
</tr>
<tr>
<td>New hire rate by gender²</td>
<td>N/A</td>
<td>Female: 16.3%, Male: 14.1%</td>
</tr>
<tr>
<td>% employee engagement³</td>
<td>N/A</td>
<td>70.0%</td>
</tr>
</tbody>
</table>

### Health and Safety Performance*

<table>
<thead>
<tr>
<th></th>
<th>As reported in 2017 GSR Report</th>
<th>Data per 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Recordable Incident Rate (Recordable cases per 200,000 hours worked)</td>
<td>0.51</td>
<td>0.53</td>
</tr>
<tr>
<td>Total DART Incident Rate (DART cases per 200,000 hours worked)</td>
<td>0.38</td>
<td>0.39</td>
</tr>
<tr>
<td>Total Lost Time Incident Rate (Lost time cases per 200,000 hours worked)</td>
<td>0.30</td>
<td>0.34</td>
</tr>
<tr>
<td>Number of sites certified to OHSAS 18001</td>
<td>5</td>
<td>12</td>
</tr>
<tr>
<td>Number of sites certified to the British Safety Council</td>
<td>N/A</td>
<td>2</td>
</tr>
</tbody>
</table>

*Data as of January 2019. Information may be restated due to the availability of additional data. Includes data for manufacturing, packaging, research and development, and distribution sites based on direct operational control.

¹Based on Mylan's HR information system
²Reasons include retirement, mutual agreement and others
³See Chapter Two, Better Employee Health.
⁴Annual incident rates are calculated per 100 employees. Assuming the average employee works 2,000 hours per year, 100 employees equals 200,000 hours worked.
### BETTER ENVIRONMENTAL HEALTH

<table>
<thead>
<tr>
<th>Environmental External Certifications</th>
<th>As reported in 2017 GSR Report</th>
<th>Data per 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of sites certified to ISO 14001</td>
<td>N/A¹</td>
<td>20</td>
</tr>
<tr>
<td>Number of sites certified to ISO 50001</td>
<td>N/A¹</td>
<td>8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Water Use &amp; Discharge Summary (thousand m³)</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total water supply</td>
<td>3,096</td>
<td>3,136</td>
<td>3,244</td>
<td>3,299</td>
</tr>
<tr>
<td>Total water recycled and reused</td>
<td>133</td>
<td>370</td>
<td>424</td>
<td>467</td>
</tr>
<tr>
<td>Total water discharged</td>
<td>1,669</td>
<td>1,613</td>
<td>1,616</td>
<td>1,554</td>
</tr>
<tr>
<td>Sites with zero liquid discharge (ZLD) systems</td>
<td>6</td>
<td>7</td>
<td>9</td>
<td>10</td>
</tr>
</tbody>
</table>

- Where applicable, prior year data have been restated due to improved data quality.
- Includes data for manufacturing, packaging, research and development, and distribution sites based on direct operational control.
- Total wastewater discharge includes sanitary/domestic sewage.
- Some data include estimates and may be updated at a later time when more accurate data is available.

In 2017, Mylan only reported on its API site certifications.
### Water Use by Sources (thousand m³)

<table>
<thead>
<tr>
<th>Source</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Municipal / Third party</td>
<td>3,016</td>
<td>3,056</td>
<td>3,148</td>
<td>3,179</td>
</tr>
<tr>
<td>On-site borewell</td>
<td>73</td>
<td>73</td>
<td>89</td>
<td>112</td>
</tr>
<tr>
<td>Rainwater</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Other</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
</tbody>
</table>

### Waste Management (thousand tonnes)

<table>
<thead>
<tr>
<th>Category</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total waste generated</td>
<td>56</td>
<td>59</td>
</tr>
<tr>
<td>Hazardous waste</td>
<td>36</td>
<td>40</td>
</tr>
<tr>
<td>Non-hazardous waste</td>
<td>20</td>
<td>19</td>
</tr>
<tr>
<td>Percentage of waste recycled or sent to energy recovery</td>
<td>68%</td>
<td>69%</td>
</tr>
<tr>
<td>Significant spills</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

- Where applicable, prior year data have been restated due to improved data quality.
- Includes data for manufacturing, packaging, research and development, and distribution sites based on direct operational control.
- Total wastewater discharge includes sanitary/domestic sewage.
- Some data include estimates and may be updated at a later time when more accurate data is available.
### Energy Purchased (GWh)

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total energy purchased</td>
<td>542</td>
<td>553</td>
<td>568</td>
<td>590</td>
</tr>
<tr>
<td>Renewable energy sources</td>
<td>16</td>
<td>36</td>
<td>56</td>
<td>72</td>
</tr>
<tr>
<td>Non-renewable energy sources</td>
<td>526</td>
<td>517</td>
<td>512</td>
<td>518</td>
</tr>
<tr>
<td>Purchased Energy Intensity Ratio (GWh / million USD revenue)</td>
<td>0.06</td>
<td>0.05</td>
<td>0.05</td>
<td>0.05</td>
</tr>
</tbody>
</table>

### Greenhouse Gas Emissions (thousand tonnes CO2e)

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total GHG Emissions</td>
<td>706</td>
<td>714</td>
<td>727</td>
<td>734</td>
</tr>
<tr>
<td>Scope 1 GHG emissions</td>
<td>370</td>
<td>388</td>
<td>402</td>
<td>402</td>
</tr>
<tr>
<td>Scope 2 GHG emissions (market-based)</td>
<td>336</td>
<td>326</td>
<td>325</td>
<td>332</td>
</tr>
<tr>
<td>Total GHG Emissions Intensity Ratio (tonnes CO2e / million USD revenue)</td>
<td>75</td>
<td>65</td>
<td>61</td>
<td>64</td>
</tr>
</tbody>
</table>

- 2015 is base year for total GHG emissions.
- Scope 2 emissions are based on market-based method.
- Includes data for manufacturing, packaging, research and development, and distribution sites based on direct operational control.
- Data from 2015–2018 have been adjusted to account for acquisitions and divestitures, in accordance with the methodology prescribed in the WRI Greenhouse Gas Protocol.
- Excludes data and sources from commercial, employee travel and commutes, small administrative/lab sites, small warehouses and other business transportation.
- Data do not include process emissions from manufacturing or emissions from insignificant sources such as welding gases, lab gases, fire extinguishers, dry ice, etc.
- All solvent combustion in air pollution control devices in Scope 1 emissions is treated as ethanol.
- 2017 GHG emissions data were verified by a third-party to a reasonable level of assurance using the methodology of the GHG Protocol issued by the World Business Council for Sustainable Development and the World Resources Institute. 2018 third party data verification is in progress.
- Energy and GHG Emissions intensity ratios use revenue as a denominator in million USD.
- Where applicable, prior year data have been restated due to improved data quality.
- Some data include estimates and may be updated at a later time when more accurate data are available.
## OVERSIGHT AND COMPLIANCE

### Business Ethics and Compliance Training at Mylan

<table>
<thead>
<tr>
<th>Training Category</th>
<th>As reported in 2017 GSR Report</th>
<th>Data per 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>% business partners who interact with government officials on our behalf, trained on our Anti-Corruption Policy and procedures</td>
<td>91%</td>
<td>96%</td>
</tr>
<tr>
<td>% of employees trained in Mylan’s Code of Business Conduct and Ethics (of employees assigned this training)</td>
<td>100%</td>
<td>96%</td>
</tr>
<tr>
<td>% of employees trained in Mylan’s Anti-Corruption Policy and related laws (of employees assigned this training)</td>
<td>98%</td>
<td>100%</td>
</tr>
<tr>
<td>% of employees trained in Mylan’s Fair Competition Policy (of employees assigned this training)</td>
<td>99%</td>
<td>96%</td>
</tr>
</tbody>
</table>
Collaborating to Improve Access

Working with global partners enables Mylan to expand access to high quality medicine. We routinely collaborate with industry associations, global public health entities, commerce organizations, governments, non-governmental organizations (NGOs) and others to help create better health for a better world. The following are some examples.

**COMMERCE ORGANIZATIONS**
- USIBC (US-India Business Council)
- U.S. Chamber of Commerce

**GLOBAL PUBLIC HEALTH ORGANIZATIONS**
- UN Global Compact
- WHO (World Health Organization)

**INDUSTRY ASSOCIATIONS**
- Association for Accessible Medicines (AAM)
- AESEG (Spanish Generic Medicines Association)
- APOGEN (Portuguese Association of Generic Medicines and Biosimilars)
- AssoGenerici (Italy Association of Generic Medicines and Biosimilars)
- BGMA (British Generic Manufacturers Association)
- BioWV
- BOGIN (Netherlands Association for Biosimilars and Generic Medicines)
- CGPA (Canada Generic Pharmaceutical Association)
- GEMME (French Generics-maker Association)
- GBMA (Australia Generic and Biosimilar Medicines Association)
- GENAS (Slovak Association of Generic producers)
- IGBA (International Generic and Biosimilar Medicines Association)
- JBSA (Japan Biosimilar Association)
- JGA (Japan Generic Medicines Association)
- Medicines for Europe
- Medicines for Ireland
- NZSMI – New Zealand Self-Medication Industry
- Prognerika (German Generic Association)
INFECTIONOUS DISEASE PARTNERS
Bill and Melinda Gates Foundation
Clinton Health Access Initiative
Gilead Sciences
Global Fund to Fight AIDS, TB, and Malaria
International AIDS Society
OPTIMIZE Consortium
Otsuka Pharmaceuticals
UNAIDS
President’s Emergency Plan for AIDS Relief (PEPFAR)
St. Stephen’s AIDS Trust
TB Alliance
UNITAID
ViiV Healthcare

PROFESSIONAL ORGANIZATIONS
Regulatory Affairs Professional Society (RAPS)
PPSWG (Pharmaceutical Product Stewardship Working Group)

QUALITY AND REGULATORY AUTHORITIES
Drug Information Association (DIA)
FDA Alumni Association and Alliance for Stronger FDA
FDA Drug Shortage Committee
GDUFA/BSUFA Implementation/Negotiation Teams
ICH (International Council for Harmonisation)
IPAC-RS (International Pharmaceutical Aerosol Consortium on Regulation & Science)
PDA (Parenteral Drug Association)
USP (United States Pharmacopeia)

MANUFACTURING ASSOCIATIONS
Alliance for Global Pharmaceutical Serialization
AMR Industry Alliance
CII (Confederation of Indian Industries)
Global Pharmaceutical Manufacturing Leadership Forum
ISPE (International Society for Pharmaceutical Engineering)
Pharmaceutical Manufacturers Association of Tokyo (PMAT)

WOMEN’S HEALTH
United Nations Population Fund
U.N. Every Woman Every Child initiative

PRODUCT ASSOCIATIONS
Consumer Healthcare Products Association
NPA (Natural Products Association)
Mylan has more than **40 manufacturing sites** in various locations around the world.¹

<table>
<thead>
<tr>
<th>REST OF WORLD</th>
<th>EUROPE</th>
<th>NORTH AMERICA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ahmedabad, India</td>
<td>Chatillon, France</td>
<td>Somerset, N.J.</td>
</tr>
<tr>
<td>Aurangabad, India</td>
<td>Confienza, Italy</td>
<td>Caguas, P.R.</td>
</tr>
<tr>
<td>Bangalore, India</td>
<td>Damastown, Ireland</td>
<td>Morgantown, W.Va.</td>
</tr>
<tr>
<td>Carole Park, Australia</td>
<td>Dublin, Ireland</td>
<td>Rockford, Ill.</td>
</tr>
<tr>
<td>Hosur, India</td>
<td>Galway, Ireland</td>
<td>San Antonio, Texas</td>
</tr>
<tr>
<td>Hyderabad, India</td>
<td>Komarom, Hungary</td>
<td>St. Albans, Vermont</td>
</tr>
<tr>
<td>Indore, India</td>
<td>Merignac, France</td>
<td>Sugar Land, Texas</td>
</tr>
<tr>
<td>Jadcherla, India</td>
<td>Meyzieu, France</td>
<td></td>
</tr>
<tr>
<td>Jaggiahpeta, India</td>
<td>Troisdorf, Germany</td>
<td></td>
</tr>
<tr>
<td>Johannesburg, South Africa</td>
<td>Warsaw, Poland</td>
<td></td>
</tr>
<tr>
<td>Katsuyama, Japan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mumbai, India</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nashik, India</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sarigam, India</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vizag, India</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zambia, Africa</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Types of Mylan Products**

- Biosimilar and insulin analogs
- Respiratory
- Complex sterile products
- Dermatological and transdermals
- Complex OSD
- Modified-release dosage forms
- OTC/parapharmaceuticals
- High potency
- Traditional generics

**Participation in relevant patient assistance and government-sponsored healthcare or tender programs**

Mylan provided patient assistance for 19 products in the U.S. in 2018; operates the Ashray program for Hep C and Hertraz patients in India and participates in various government-sponsored healthcare or tender programs around the world.

**Managing Political Contributions Responsibly**

Mylan’s Global Political Contributions and Activity Policy guides our approach to political contributions. It is overseen by Mylan’s Compliance Committee and applies to all company personnel. Only to the extent allowed by law, the company may directly contribute to political candidates and political organizations. This is relevant primarily for Mylan’s U.S. subsidiaries and Mylan’s Political Action Committee, a voluntary, nonpartisan, employee-run committee. Political contributions are made in accordance with U.S. campaign finance laws. In addition, Mylan files a quarterly report of expenses associated with lobbying the federal government² in accordance with the U.S. Lobbying Disclosure Act. The report can be found on the U.S. Senate Office of Public Records website or the U.S. House of Representatives Office of the Clerk website. Mylan’s semi-annual Political Contribution & Trade Association Memberships report is available on our website.

¹As of the publication of this report and does not include one site already announced for closure. Some locations have more than one manufacturing site. Also represents packaging facilities.

Honoring Our Commitment as a Publicly Traded Company

Mylan N.V. is listed on the NASDAQ stock exchange in New York. Its corporate seat is Amsterdam, Netherlands, with its principal executive office located in Hatfield, Hertfordshire, England.

The global headquarters of the Mylan group is Canonsburg, Pennsylvania, U.S. It is at this location where the CEO and other executive officers of the group carry out the day-to-day conduct of our worldwide business.

Mylan N.V. is managed and controlled under the oversight of the company’s board of directors in the U.K., where the board generally meets. Each director is elected annually by the company’s shareholders. Certain of the directors’ duties, rights and responsibilities are detailed in the company’s Articles of Association, Board Rules and Corporate Governance Principles. Mylan is subject to applicable rules, regulations and/or listing standards of the U.S. Securities and Exchange Commission, NASDAQ and the Dutch Corporate Governance Code.

UN GLOBAL COMPACT 10 PRINCIPLES

HUMAN RIGHTS

1: Businesses should support and respect the protection of internationally proclaimed human rights, and
2: make sure that they are not complicit in human rights abuses.

LABOR

3: Businesses should uphold the freedom of association and the effective recognition of the right to collective bargaining,
4: the elimination of all forms of forced and compulsory labor,
5: the effective abolition of child labor, and
6: the elimination of discrimination in respect of employment and occupation.

ENVIRONMENT

7: Businesses should support a precautionary approach to environmental challenges,
8: undertake initiatives to promote greater environmental responsibility, and
9: encourage the development and diffusion of environmentally friendly technologies.

ANTI-CORRUPTION

10: Businesses should work against corruption in all its forms, including extortion and bribery.

THE SDGs ESPECIALLY RELEVANT TO MYLAN

## GRI 102: General Disclosures*

<table>
<thead>
<tr>
<th>Disclosure</th>
<th>Description</th>
<th>Cross-Reference or Answer</th>
<th>SDG</th>
<th>UNGC Principle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Organizational Profile</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-1</td>
<td>Name of the organization</td>
<td>Mylan N.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-2</td>
<td>Activities, brands, products and services</td>
<td>10-13, 17-25, 2018 Form 10-K</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-3</td>
<td>Location of headquarters</td>
<td>Appendix, p. 81</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-4</td>
<td>Location of operations</td>
<td>Appendix, p. 80-81, 2018 Form 10-K</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-5</td>
<td>Ownership and legal form</td>
<td>Appendix, p. 81, 2018 Form 10-K</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-6</td>
<td>Markets served</td>
<td>11, 13, 17-25, Appendix, p. 68-70</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-7</td>
<td>Scale of the organization</td>
<td>4-5, 13, 59, Appendix, p. 68-70, 80, 2018 Form 10-K</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-8</td>
<td>Information on employees and other workers</td>
<td>33, Appendix, p. 71-73</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>A significant portion of Mylan’s activities are performed by workers who are employees, and there are no significant variations in our employee figures annually.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-9</td>
<td>Supply chain</td>
<td>12-13, 28, 30, 65-66</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-10</td>
<td>Significant changes to the organization and its supply chain</td>
<td>35, 2018 Form 10-K</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-11</td>
<td>Precautionary Principle or approach</td>
<td>27-30, 39-43, 60, 65-66</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Mylan’s 2018 Global Social Responsibility Progress Report applies the 2016 version of the GRI Standards; “2016” refers to the Standards issue date, not the date of information presented in this report.
<table>
<thead>
<tr>
<th>Disclosure</th>
<th>Description</th>
<th>Cross-Reference or Answer</th>
<th>SDG</th>
<th>UNGC Principle</th>
</tr>
</thead>
<tbody>
<tr>
<td>102-13</td>
<td>Membership of associations</td>
<td>42-43, 45-50 Appendix, p. 78-79</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-14</td>
<td>Statement from senior decision-maker</td>
<td>6, 8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-15</td>
<td>Key impacts, risks and opportunities</td>
<td>6, 8, 10-13, 17-31, 33-50, 53, 59-67</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Strategy**

<table>
<thead>
<tr>
<th>Disclosure</th>
<th>Description</th>
<th>Cross-Reference or Answer</th>
<th>SDG</th>
<th>UNGC Principle</th>
</tr>
</thead>
<tbody>
<tr>
<td>102-16</td>
<td>Values, principles, standards and norms of behavior</td>
<td>Inside front cover, 6-11, 27-28, 30-31, 35-37, 39, 42-43, 60-67 Mylan Values</td>
<td>16</td>
<td>2, 5 &amp; 10</td>
</tr>
<tr>
<td>102-17</td>
<td>Mechanisms for advice and concerns about ethics</td>
<td>60, 62-63</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Ethics and Integrity**

<table>
<thead>
<tr>
<th>Disclosure</th>
<th>Description</th>
<th>Cross-Reference or Answer</th>
<th>SDG</th>
<th>UNGC Principle</th>
</tr>
</thead>
<tbody>
<tr>
<td>102-16</td>
<td>Values, principles, standards and norms of behavior</td>
<td>Inside front cover, 6-11, 27-28, 30-31, 35-37, 39, 42-43, 60-67 Mylan Values</td>
<td>16</td>
<td>2, 5 &amp; 10</td>
</tr>
<tr>
<td>102-17</td>
<td>Mechanisms for advice and concerns about ethics</td>
<td>60, 62-63</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Governance**

<table>
<thead>
<tr>
<th>Disclosure</th>
<th>Description</th>
<th>Cross-Reference or Answer</th>
<th>SDG</th>
<th>UNGC Principle</th>
</tr>
</thead>
<tbody>
<tr>
<td>102-18</td>
<td>Governance structure</td>
<td>39, 60, 62, 2018 Form 10-K</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-20</td>
<td>Executive-level responsibility for economic, environmental and social topics</td>
<td>6, 8, 39, 60, 62</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-21</td>
<td>Consulting stakeholders on economic, environmental and social topics</td>
<td>6, 8-9, 42, 45-50, 59-60</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-22</td>
<td>Composition of the highest governance body and its committees</td>
<td>60 Appendix, p. 72 2018 Form 10-K Mylan.com/Leadership Mylan.com/corporategovernance</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Stakeholder Engagement**

<table>
<thead>
<tr>
<th>Disclosure</th>
<th>Description</th>
<th>Cross-Reference or Answer</th>
<th>SDG</th>
<th>UNGC Principle</th>
</tr>
</thead>
<tbody>
<tr>
<td>102-40</td>
<td>List of stakeholder groups</td>
<td>8, 59, 78-79 Community Customers Employees Partners Patients Shareholders</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Collectives bargaining agreements</td>
<td>36 Mylan recognizes and respects the rights of employees to representation and collective bargaining. We currently do not keep company-wide records on the percentage of employees covered by collective bargaining agreements.</td>
<td>3</td>
<td></td>
</tr>
</tbody>
</table>

*Mylan’s 2018 Global Social Responsibility Progress Report applies the 2016 version of the GRI Standards; “2016” refers to the Standards issue date, not the date of information presented in this report.
<table>
<thead>
<tr>
<th>Disclosure</th>
<th>Description</th>
<th>Cross-Reference or Answer</th>
<th>SDG</th>
<th>UNGC Principle</th>
</tr>
</thead>
<tbody>
<tr>
<td>102-42</td>
<td>Identifying and selecting stakeholders</td>
<td>9, 42, 45-50, 59-60</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-43</td>
<td>Approach to stakeholder engagement</td>
<td>8-9, 42, 45-50, 59-60</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-44</td>
<td>Key topics and concerns raised</td>
<td>6, 8-9, 42, 45-50, 59-60</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Reporting Practice**

<table>
<thead>
<tr>
<th>Disclosure</th>
<th>Description</th>
<th>Cross-Reference or Answer</th>
<th>SDG</th>
<th>UNGC Principle</th>
</tr>
</thead>
<tbody>
<tr>
<td>102-45</td>
<td>Entities included in the consolidated financial statements</td>
<td>2018 Form 10-K</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-46</td>
<td>Defining report content and topic boundaries</td>
<td>9 We completed our first formal priority topic analysis in 2018 to confirm our GSR priorities based on the topics of highest importance to the company and key stakeholders. We identify where impacts occur for each priority topic in the Topic Boundary section (GRI 103) of the GRI Index.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-47</td>
<td>List of material topics</td>
<td>9 Topic Boundary section (GRI 103) of the GRI Index</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-48</td>
<td>Restatements of information</td>
<td>Appendix, p. 74-76</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-49</td>
<td>Changes in reporting</td>
<td>None</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-50</td>
<td>Reporting period</td>
<td>Calendar year 2018, Jan. 1 - Dec. 31</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-51</td>
<td>Date of most recent report</td>
<td>5/5/18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-52</td>
<td>Reporting cycle</td>
<td>Annual</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-53</td>
<td>Contact point for questions regarding the report</td>
<td>Should you have questions or feedback, please contact us at <a href="mailto:GSR@Mylan.com">GSR@Mylan.com</a>.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-54</td>
<td>Claims of reporting in accordance with the GRI Standards</td>
<td>Mylan's 2018 GSR Report is prepared in accordance with Global Reporting Initiative (GRI) Standards, core level.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-55</td>
<td>GRI content index</td>
<td>82-89</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-56</td>
<td>External assurance</td>
<td>Mylan's 2018 Global Social Responsibility Progress Report has not been assured by a third party. Mylan's reporting to the 2018 CDP Climate Change and Water Security Programs was verified by an external party.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Mylan’s 2018 Global Social Responsibility Progress Report applies the 2016 version of the GRI Standards; "2016" refers to the Standards issue date, not the date of information presented in this report.*
### GRI 103: Topics and Topic Boundaries*

<table>
<thead>
<tr>
<th>Mylan's Priority (Material) Topics</th>
<th>Management Approach Cross-Reference</th>
<th>Relevant External Entities</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Economic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GRI 203: Indirect Economic Impacts 2016</td>
<td>10-13, 17-29, 45-50, 53-57, 60</td>
<td>Communities, Customers, Patients</td>
</tr>
<tr>
<td><strong>Environment</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GRI 301: Materials 2016</td>
<td>27-28, 31, 41, 65</td>
<td>Communities, Customers, Governments, Patients, Suppliers</td>
</tr>
<tr>
<td></td>
<td>[Environmental Stewardship, Oversight and Compliance]</td>
<td></td>
</tr>
<tr>
<td><strong>Social</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GRI 402: Labor/Management Relations 2016</td>
<td>36, 60</td>
<td>Communities, Governments, Shareholders</td>
</tr>
<tr>
<td>GRI 404: Training and Education 2016</td>
<td>33-36</td>
<td>N/A</td>
</tr>
<tr>
<td>GRI 416: Customer Health and Safety 2016</td>
<td>26-30, 50, 60</td>
<td>Communities, Customers, Governments, Patients, Shareholders</td>
</tr>
</tbody>
</table>

*Mylan’s 2018 Global Social Responsibility Progress Report applies the 2016 version of the GRI Standards; “2016” refers to the Standards issue date, not the date of information presented in this report.
## GRI 200-400: Standard Disclosures*

<table>
<thead>
<tr>
<th>Topics</th>
<th>Disclosure</th>
<th>Description</th>
<th>Cross-Reference or Answer</th>
<th>SDG</th>
<th>UNGC Principle</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Economic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GRI 201: Economic Performance 2016**</td>
<td>201-1</td>
<td>Direct economic value generated and distributed</td>
<td>2018 Form 10-K</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GRI 203: Indirect Economic Impacts 2016</td>
<td>203-1</td>
<td>Infrastructure investments and services supported</td>
<td>24, 55-57</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>203-2</td>
<td>Indirect economic impacts</td>
<td>10-13, 17-26, 45-50, 53-57, 60</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>GRI 205: Anti-corruption 2016**</td>
<td>205-2</td>
<td>Communication and training about anti-corruption policies and procedures</td>
<td>62-64</td>
<td>16</td>
<td>10</td>
</tr>
<tr>
<td>GRI 206: Anti-competitive Behavior 2016</td>
<td>206-01</td>
<td>Legal actions for anti-competitive behavior, anti-trust and monopoly practice</td>
<td>2018 Form 10-K</td>
<td></td>
<td>16</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Environmental</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GRI 301: Materials 2016</td>
<td>301-1</td>
<td>Materials used by weight or volume</td>
<td>12, 41 Details on material types, sources and percentage of renewable content, in addition to the information on energy, water and waste is not provided.</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>GRI 302: Energy 2016**</td>
<td>302-4</td>
<td>Reduction of energy consumption</td>
<td>43 Appendix, p. 76</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>303-1</td>
<td>Interactions with water as a shared resource</td>
<td>39-40 Appendix, p. 74-75</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td>GRI 303: Water and Effluents, 2018**</td>
<td>303-2</td>
<td>Management of water discharge-related impacts</td>
<td>39-40, 42 Appendix, p. 74-75</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>303-3</td>
<td>Water withdrawal</td>
<td>Appendix, p. 74-75</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>303-4</td>
<td>Water discharge</td>
<td>Appendix, p. 74</td>
<td></td>
<td>8</td>
</tr>
</tbody>
</table>

*Mylan’s 2018 Global Social Responsibility Progress Report applies the 2016 version of the GRI Standards; "2016" refers to the Standards issue date, not the date of information presented in this report.  
**Additional disclosures not related to material GRI topics
<table>
<thead>
<tr>
<th>Topics</th>
<th>Disclosure</th>
<th>Description</th>
<th>Cross-Reference or Answer</th>
<th>SDG</th>
<th>UNGC Principle</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GRI 305: Emissions 2016</strong></td>
<td>305-1</td>
<td>Scope 1 GHG emissions</td>
<td>43 Appendix, p. 76</td>
<td>12</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>305-2</td>
<td>Scope 2 GHG emissions</td>
<td>43 Appendix, p. 76</td>
<td>12</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>305-5</td>
<td>Reduction of GHG emissions</td>
<td>43 Appendix, p. 76</td>
<td>12</td>
<td>13</td>
</tr>
<tr>
<td><strong>GRI 306: Effluents and Waste 2016</strong></td>
<td>306-2</td>
<td>Waste by type and disposal method</td>
<td>41 Appendix, p. 75</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>306-3</td>
<td>Significant spill</td>
<td></td>
<td></td>
<td>12</td>
</tr>
<tr>
<td><strong>GRI 307: Environmental Compliance 2016</strong></td>
<td>307-1</td>
<td>Non-compliance with environmental laws and regulations</td>
<td></td>
<td>12</td>
<td></td>
</tr>
<tr>
<td><strong>Social</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GRI 401: Employment 2016</strong></td>
<td>401-1</td>
<td>New employee hires and employee turnover</td>
<td>34 Appendix, p. 73</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>401-2</td>
<td>Full-time benefits not provided to temporary/part-time employees</td>
<td>Mylan Careers</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GRI 402: Labor/Management Relations 2016</strong></td>
<td>402-1</td>
<td>Minimum notice periods regarding operational changes</td>
<td>35 Minimum notice periods regarding operational changes impacting employees, including continued employment, vary across the company, as determined by legislation, local and regional policies and practices, individual employment contracts, and collective bargaining agreements, as applicable.</td>
<td>8</td>
<td></td>
</tr>
</tbody>
</table>

*Mylan's 2018 Global Social Responsibility Progress Report applies the 2016 version of the GRI Standards; “2016” refers to the Standards issue date, not the date of information presented in this report.
**Additional disclosures not related to material GRI topics
<table>
<thead>
<tr>
<th>Topics</th>
<th>Disclosure</th>
<th>Description</th>
<th>Cross-Reference or Answer</th>
<th>SDG</th>
<th>UNGC Principle</th>
</tr>
</thead>
<tbody>
<tr>
<td>GRI 403: Occupational Health and Safety 2018**</td>
<td>403-1</td>
<td>Occupational health and safety management system</td>
<td>37, 39 Appendix, p. 73 Global Health Safety Policy</td>
<td>3, 8</td>
<td></td>
</tr>
<tr>
<td></td>
<td>403-2</td>
<td>Hazard identification, risk assessment and incident investigation</td>
<td>37, 39 Appendix, p. 73 Global Health Safety Policy</td>
<td>3, 8</td>
<td></td>
</tr>
<tr>
<td></td>
<td>403-6</td>
<td>Promotion of worker health</td>
<td>36-37 Mylan Values</td>
<td>3, 8</td>
<td></td>
</tr>
<tr>
<td></td>
<td>403-9</td>
<td>Work-related injuries</td>
<td>37 Appendix, p.73</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>GRI 404: Training and Education 2016**</td>
<td>404-1</td>
<td>Average hours of training per year per employee</td>
<td>34</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>404-2</td>
<td>Programs for upgrading employee skills and transition assistance programs</td>
<td>34-35 Mylan Careers</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td></td>
<td>404-3</td>
<td>Percentage of employees receiving regular performance and career development reviews</td>
<td>35 Appendix, p. 72</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>GRI 405: Diversity and Equal Opportunity 2016**</td>
<td>405-1</td>
<td>Diversity of governance bodies and employees</td>
<td>36 Appendix, p. 71-72</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>GRI 412: Human Rights Assessment 2016**</td>
<td>412-2</td>
<td>Employee training on HR policies or procedures</td>
<td>62-63, 66-67</td>
<td>1,2,3,4,5</td>
<td></td>
</tr>
<tr>
<td>GRI 413: Local Communities 2016**</td>
<td>413-1</td>
<td>Operations with local community engagement, impact assessments, and development programs</td>
<td>23-24, 53-57</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>GRI 415: Public Policy 2016</td>
<td>415-1</td>
<td>Political contributions</td>
<td>Appendix, p. 80</td>
<td>16</td>
<td>10</td>
</tr>
</tbody>
</table>

*Mylan’s 2018 Global Social Responsibility Progress Report applies the 2016 version of the GRI Standards; “2016” refers to the Standards issue date, not the date of information presented in this report.

**Additional disclosures not related to material GRI topics
<table>
<thead>
<tr>
<th>Topics</th>
<th>Disclosure</th>
<th>Description</th>
<th>Cross-Reference or Answer</th>
<th>SDG</th>
<th>UNGC Principle</th>
</tr>
</thead>
<tbody>
<tr>
<td>GRI 416: Customer Health and Safety 2016</td>
<td>416-1</td>
<td>Assessment of the health and safety impacts of product and service categories</td>
<td>27-29</td>
<td></td>
<td>3 12</td>
</tr>
<tr>
<td></td>
<td></td>
<td>As part of Mylan’s PV program, all products are monitored and assessed for safety impact on an ongoing basis.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GRI 417: Marketing and Labeling 2016**</td>
<td>417-1</td>
<td>Requirements for product and service information and labeling</td>
<td>27-29, 61</td>
<td></td>
<td>3 12</td>
</tr>
</tbody>
</table>

*Mylan’s 2018 Global Social Responsibility Progress Report applies the 2016 version of the GRI Standards; “2016” refers to the Standards issue date, not the date of information presented in this report.

**Additional disclosures not related to material GRI topics
This document contains "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, statements about future expectations, ability to achieve future goals, and any other statements regarding Mylan’s future operations, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competition, and other expectations and targets for future periods. These may often be identified by the use of words such as "will," "may," "could," "should," "would," "project," "believe," "anticipate," "expect," "plan," "estimate," "forecast," "potential," "pipeline," "intend," "continue," "target," "seek" and variations of these words or comparable words. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: actions and decisions of healthcare and pharmaceutical regulators; failure to achieve expected or targeted future financial and operating performance and results; uncertainties regarding future demand, pricing and reimbursement for our products; any regulatory, legal, or other impediments to Mylan’s ability to bring new products to market, including, but not limited to, where Mylan uses its business judgment and decides to manufacture, market, and/or sell products, directly or through third parties, notwithstanding the fact that allegations of patent infringement(s) have not been finally resolved by the courts (i.e., an "at-risk launch"); success of clinical trials and Mylan’s ability to execute on new product opportunities; any changes in or difficulties with our manufacturing facilities, including with respect to our remediation and restructuring activities, supply chain or inventory or our ability to meet anticipated demand; the scope, timing, and outcome of any ongoing legal proceedings, including government investigations, and the impact of any such proceedings on our financial condition, results of operations, and/or cash flows; the ability to meet expectations regarding the accounting and tax treatments of acquisitions, including Mylan’s acquisition of Mylan Inc. and Abbott Laboratories’ non-U.S. developed markets specialty and branded generics business; changes in relevant tax and other laws, including but not limited to changes in the U.S. tax code and healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any significant breach of data security or data privacy or disruptions to our information technology systems; the ability to protect intellectual property and preserve intellectual property rights; the effect of any changes in customer and supplier relationships and customer purchasing patterns; the ability to attract and retain key personnel; the impact of competition; identifying, acquiring, and integrating complementary or strategic acquisitions of other companies, products, or assets being more difficult, time-consuming or costly than anticipated; the possibility that Mylan may be unable to achieve expected synergies and operating efficiencies in connection with strategic acquisitions, strategic initiatives or restructuring programs within the expected time-frames or at all; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions and global exchange rates; and inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements, and the providing of estimates of financial measures, in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and related standards or on an adjusted basis. For more detailed information on the risks and uncertainties associated with Mylan’s business activities, see the risks described in Mylan’s Annual Report on Form 10-K for the year ended Dec. 31, 2018, and our other filings with the Securities and Exchange Commission (“SEC”). You can access Mylan’s filings with the SEC through the SEC website at www.sec.gov or through our website, and Mylan strongly encourages you to do so. Mylan routinely posts information that may be important to investors on our website at investor.mylan.com, and we use this website address as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Mylan undertakes no obligation to update any statements herein for revisions or changes after the date of this document, which is April 2, 2019.